OnCo Edge

Paper: Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care.

2026-09-18T00:00:00Z

Published in J Clin Oncol on 18 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.

18 September 2026, J Clin Oncol.

On OnCo: Early-stage classical Hodgkin lymphoma

Paper: Phase III Trials Test First-Line Options in Advanced NSCLC.

2026-09-18T00:00:00Z

Published in Cancer Discov on 18 September 2026; matched the OnCo record for Amivantamab.

18 September 2026, Cancer Discov.

On OnCo: Amivantamab, Ivonescimab, Zipalertinib

Paper: γδ T cells modulate anti-tumor immunity in small cell lung cancer.

2026-09-18T00:00:00Z

Published in Cancer Cell on 18 September 2026; matched the OnCo record for Zoledronic acid.

18 September 2026, Cancer Cell.

On OnCo: Zoledronic acid

Paper: An expert-level generalist AI for abdominal CT diagnosis.

2026-09-17T00:00:00Z

Published in Science on 17 September 2026; matched the OnCo record for RaDaR.

17 September 2026, Science.

On OnCo: RaDaR

Paper: Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.

2026-09-17T00:00:00Z

Published in Cancer Discov on 17 September 2026; matched the OnCo record for YL201.

17 September 2026, Cancer Discov.

On OnCo: YL201

Paper: Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma.

2026-09-17T00:00:00Z

Published in Nat Med on 17 September 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.

17 September 2026, Nat Med.

On OnCo: Diffuse midline glioma, H3 K27-altered

Paper: Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

2026-09-17T00:00:00Z

Published in Ann Oncol on 17 September 2026; matched the OnCo record for Goserelin / leuprolide.

17 September 2026, Ann Oncol.

On OnCo: Goserelin / leuprolide

Paper: Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA-Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer.

2026-09-16T00:00:00Z

Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Localised anal squamous cell carcinoma.

16 September 2026, J Clin Oncol.

On OnCo: Localised anal squamous cell carcinoma

Paper: Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

2026-09-16T00:00:00Z

Published in Cancer Cell on 16 September 2026; matched the OnCo record for Adebrelimab.

16 September 2026, Cancer Cell.

On OnCo: Adebrelimab

Paper: Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

2026-09-16T00:00:00Z

Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Trastuzumab rezetecan.

16 September 2026, J Clin Oncol.

On OnCo: Trastuzumab rezetecan

Approval: FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer

2026-09-09T00:00:00Z

On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

9 September 2026, FDA.

On OnCo: Sevabertinib, Non-small-cell lung cancer, HER2-mutant non-small-cell lung cancer, HER2

Issue: OnCo weekly, 2026-09-22

2026-09-22T00:00:00Z

416 changelog entries, 1 regulatory event, 2 upcoming dates, 2 corrections.

22 September 2026, OnCo weekly issue.

Paper: Successful management of paediatric chronic SIAD with oral urea: report of two cases.

2026-09-22T00:00:00Z

Published in J Pediatr Endocrinol Metab on 22 September 2026; matched the OnCo record for Paediatric low-grade glioma.

22 September 2026, J Pediatr Endocrinol Metab.

On OnCo: Paediatric low-grade glioma

Paper: Author Correction: Erythropoietin receptor on cDC1s dictates immune tolerance.

2026-09-15T00:00:00Z

Published in Nature on 15 September 2026; matched the OnCo record for Erythropoietin receptor.

15 September 2026, Nature.

On OnCo: Erythropoietin receptor

Paper: Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial.

2026-09-15T00:00:00Z

Published in Nat Med on 15 September 2026; matched the OnCo record for GFH375.

15 September 2026, Nat Med.

On OnCo: GFH375

Paper: A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

2026-09-21T00:00:00Z

Published in Blood Cancer Discov on 21 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

21 September 2026, Blood Cancer Discov.

On OnCo: Acute lymphoblastic leukaemia, CD22

Paper: Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy.

2026-09-21T00:00:00Z

Published in Muscle Nerve on 21 September 2026; matched the OnCo record for Small intestine cancer.

21 September 2026, Muscle Nerve.

On OnCo: Small intestine cancer

Paper: Comparative Effectiveness of Antibiotic Prophylaxis Regimens in Pediatric Acute Myeloid Leukemia.

2026-09-21T00:00:00Z

Published in Pediatr Blood Cancer on 21 September 2026; matched the OnCo record for Acute myeloid leukaemia in children.

21 September 2026, Pediatr Blood Cancer.

On OnCo: Acute myeloid leukaemia in children

Paper: IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.

2026-09-21T00:00:00Z

Published in Cancer Immunol Res on 21 September 2026; matched the OnCo record for TCR-T cell therapy.

21 September 2026, Cancer Immunol Res.

On OnCo: TCR-T cell therapy

Paper: Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation.

2026-09-21T00:00:00Z

Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for Aumolertinib.

21 September 2026, Signal Transduct Target Ther.

On OnCo: Aumolertinib

Paper: Integrative Genetic and Bioinformatic Analysis of Androgen Pathway Gene Polymorphisms, Testosterone, and PSA Levels in Prostate Cancer.

2026-09-21T00:00:00Z

Published in Genet Test Mol Biomarkers on 21 September 2026; matched the OnCo record for CYP17A1.

21 September 2026, Genet Test Mol Biomarkers.

On OnCo: CYP17A1, 5-alpha-reductase type 2

Issue: OnCo weekly, 2026-09-21

2026-09-21T00:00:00Z

310 changelog entries, 1 upcoming date, 7 publications, 2 corrections.

21 September 2026, OnCo weekly issue.

Paper: Real-world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study.

2026-09-21T00:00:00Z

Published in Arthritis Care Res (Hoboken) on 21 September 2026; matched the OnCo record for Tocilizumab.

21 September 2026, Arthritis Care Res (Hoboken).

On OnCo: Tocilizumab

Paper: Ribonucleotides Amplify Mitochondrial DNA-Driven cGAS-STING Activation via FdUMP-ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy.

2026-09-21T00:00:00Z

Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for Floxuridine.

21 September 2026, Adv Sci (Weinh).

On OnCo: Floxuridine

Paper: Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

2026-09-21T00:00:00Z

Published in Clin Cancer Res on 21 September 2026; matched the OnCo record for Adavosertib.

21 September 2026, Clin Cancer Res.

On OnCo: Adavosertib, Ceralasertib, WEE1

Paper: Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.

2026-09-21T00:00:00Z

Published in Br J Dermatol on 21 September 2026; matched the OnCo record for Mogamulizumab.

21 September 2026, Br J Dermatol.

On OnCo: Mogamulizumab

Paper: Toripalimab Plus TPF as Induction Chemoimmunotherapy for the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Prospective Phase II Study.

2026-09-21T00:00:00Z

Published in Head Neck on 21 September 2026; matched the OnCo record for Toripalimab.

21 September 2026, Head Neck.

On OnCo: Toripalimab

Paper: Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

2026-09-21T00:00:00Z

Published in Arthritis Rheumatol on 21 September 2026; matched the OnCo record for Emapalumab.

21 September 2026, Arthritis Rheumatol.

On OnCo: Emapalumab

Paper: Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.

2026-09-14T00:00:00Z

Published in Nat Cancer on 14 September 2026; matched the OnCo record for FOLFIRI.

14 September 2026, Nat Cancer.

On OnCo: FOLFIRI

Paper: P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

2026-09-14T00:00:00Z

Published in J Clin Oncol on 14 September 2026; matched the OnCo record for Afatinib.

14 September 2026, J Clin Oncol.

On OnCo: Afatinib, Amivantamab, Sunvozertinib, Zipalertinib

Paper: Advancing neurofibromatosis research: a comparative review of animal models and their utility in dissecting the tumor microenvironment.

2026-09-20T00:00:00Z

Published in Lab Anim Res on 20 September 2026; matched the OnCo record for Genetically engineered mouse models.

20 September 2026, Lab Anim Res.

On OnCo: Genetically engineered mouse models

Paper: Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research.

2026-09-20T00:00:00Z

Published in Oncogene on 20 September 2026; matched the OnCo record for Humanised mouse models.

20 September 2026, Oncogene.

On OnCo: Humanised mouse models

Paper: Bridging the data latency gap: automated extraction of genomic biomarkers from unstructured clinical documents to support real-world oncology data.

2026-09-20T00:00:00Z

Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Oncotype DX.

20 September 2026, Cancer Causes Control.

On OnCo: Oncotype DX

Paper: Current Management and Investigational Therapeutic Strategies in Penile Squamous Cell Carcinoma: A Narrative Review.

2026-09-20T00:00:00Z

Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Penile cancer.

20 September 2026, Crit Rev Oncol Hematol.

On OnCo: Penile cancer

Paper: Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand? Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand?

2026-09-20T00:00:00Z

Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Belzutifan.

20 September 2026, Crit Rev Oncol Hematol.

On OnCo: Belzutifan

Paper: Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.

2026-09-20T00:00:00Z

Published in Cardiovasc Toxicol on 20 September 2026; matched the OnCo record for HER4.

20 September 2026, Cardiovasc Toxicol.

On OnCo: HER4, Strain echocardiography

Paper: Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

2026-09-20T00:00:00Z

Published in Br J Haematol on 20 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

20 September 2026, Br J Haematol.

On OnCo: Acute lymphoblastic leukaemia

Paper: Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2.

2026-09-20T00:00:00Z

Published in Acta Biomater on 20 September 2026; matched the OnCo record for CD123.

20 September 2026, Acta Biomater.

On OnCo: CD123

Paper: Longitudinal Associations of Oxaliplatin Treatment With Chemotherapy-Induced Peripheral Neuropathy in Colorectal cancer Survivors up to 2 Years Post-Treatment.

2026-09-20T00:00:00Z

Published in Int J Cancer on 20 September 2026; matched the OnCo record for CAPOX.

20 September 2026, Int J Cancer.

On OnCo: CAPOX

Paper: Predictors of perceived value of multi-cancer early detection testing: a national PRECEDE-PROCEED framework study.

2026-09-20T00:00:00Z

Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Multi-cancer early detection.

20 September 2026, Cancer Causes Control.

On OnCo: Multi-cancer early detection

Paper: Progress with FAK inhibitors in the patent literature (2020-present).

2026-09-20T00:00:00Z

Published in Expert Opin Ther Pat on 20 September 2026; matched the OnCo record for Avutometinib + defactinib.

20 September 2026, Expert Opin Ther Pat.

On OnCo: Avutometinib + defactinib

Paper: Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.

2026-09-20T00:00:00Z

Published in Future Oncol on 20 September 2026; matched the OnCo record for Avelumab.

20 September 2026, Future Oncol.

On OnCo: Avelumab

Paper: Updates to contemporary care of glioblastoma.

2026-09-20T00:00:00Z

Published in Clin Med (Lond) on 20 September 2026; matched the OnCo record for Tumour treating fields.

20 September 2026, Clin Med (Lond).

On OnCo: Tumour treating fields

Paper: A pyridone-fused imidazo[1,2-a]pyridine hybrid binds to tubulin at the vinblastine site, depolymerizes microtubules and inhibits Cancer cell proliferation.

2026-09-19T00:00:00Z

Published in Bioorg Chem on 19 September 2026; matched the OnCo record for Vinblastine.

19 September 2026, Bioorg Chem.

On OnCo: Vinblastine

Paper: Acute myeloid leukemia arising in treated chronic lymphocytic leukemia/small lymphocytic lymphoma: a challenge in analysis of lineage relationship.

2026-09-19T00:00:00Z

Published in J Hematop on 19 September 2026; matched the OnCo record for CD123.

19 September 2026, J Hematop.

On OnCo: CD123

Paper: Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers.

2026-09-19T00:00:00Z

Published in Curr Opin Oncol on 19 September 2026; matched the OnCo record for Talazoparib.

19 September 2026, Curr Opin Oncol.

On OnCo: Talazoparib, WEE1

Paper: Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.

2026-09-19T00:00:00Z

Published in EJHaem on 19 September 2026; matched the OnCo record for BCR::ABL1.

19 September 2026, EJHaem.

On OnCo: BCR::ABL1

Paper: Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

2026-09-19T00:00:00Z

Published in Mol Ther on 19 September 2026; matched the OnCo record for Plerixafor.

19 September 2026, Mol Ther.

On OnCo: Plerixafor

Paper: Distribution, socioeconomic inequalities and contributing factors of anaemia prevalence across wealth index among Indian adolescent girls: multivariate decomposition analysis of nationally representative survey.

2026-09-19T00:00:00Z

Published in BMJ Paediatr Open on 19 September 2026; matched the OnCo record for HB-200.

19 September 2026, BMJ Paediatr Open.

On OnCo: HB-200

Paper: Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study.

2026-09-19T00:00:00Z

Published in Radiother Oncol on 19 September 2026; matched the OnCo record for Limited-stage small-cell lung cancer.

19 September 2026, Radiother Oncol.

On OnCo: Limited-stage small-cell lung cancer

Paper: Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.

2026-09-19T00:00:00Z

Published in Eur J Nucl Med Mol Imaging on 19 September 2026; matched the OnCo record for Gallium-68 gozetotide.

19 September 2026, Eur J Nucl Med Mol Imaging.

On OnCo: Gallium-68 gozetotide

Paper: Hepatocellular Carcinoma With a Grade 3 Neuroendocrine Tumor Component: A Case Report.

2026-09-19T00:00:00Z

Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Grade 3 well-differentiated neuroendocrine tumour.

19 September 2026, Int J Surg Pathol.

On OnCo: Grade 3 well-differentiated neuroendocrine tumour

Paper: Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.

2026-09-19T00:00:00Z

Published in Cell Death Discov on 19 September 2026; matched the OnCo record for Lutetium-177 dotatate.

19 September 2026, Cell Death Discov.

On OnCo: Lutetium-177 dotatate, Pancreatic neuroendocrine tumours

Paper: In vivo CAR‑T cell therapy: mechanisms, clinical advances and optimization strategies.

2026-09-19T00:00:00Z

Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for In vivo CAR-T.

19 September 2026, Biochem Pharmacol.

On OnCo: In vivo CAR-T

Paper: Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen.

2026-09-19T00:00:00Z

Published in Libyan J Med on 19 September 2026; matched the OnCo record for Anal high-grade squamous intraepithelial lesions.

19 September 2026, Libyan J Med.

On OnCo: Anal high-grade squamous intraepithelial lesions, Burkitt lymphoma, CD19, CD7

Paper: Investigating the impact of margins on the management of oropharyngeal cancer treated with transoral robotic surgery: a survey of head and neck oncologists' treatment patterns.

2026-09-19T00:00:00Z

Published in Oral Oncol on 19 September 2026; matched the OnCo record for Transoral robotic surgery.

19 September 2026, Oral Oncol.

On OnCo: Transoral robotic surgery

Paper: IRF1-driven chromatin and transcriptional regulation determines the anti-tumor responses to all-trans retinoic acid across cancer types.

2026-09-19T00:00:00Z

Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for Acute promyelocytic leukaemia.

19 September 2026, Biochem Pharmacol.

On OnCo: Acute promyelocytic leukaemia

Paper: Precision therapeutic strategies for advanced gastrointestinal stromal tumors.

2026-09-19T00:00:00Z

Published in Cancer Metastasis Rev on 19 September 2026; matched the OnCo record for Ripretinib.

19 September 2026, Cancer Metastasis Rev.

On OnCo: Ripretinib

Paper: Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT.

2026-09-19T00:00:00Z

Published in Transplant Cell Ther on 19 September 2026; matched the OnCo record for CD33.

19 September 2026, Transplant Cell Ther.

On OnCo: CD33

Paper: Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA.

2026-09-19T00:00:00Z

Published in Clin Drug Investig on 19 September 2026; matched the OnCo record for Bendamustine.

19 September 2026, Clin Drug Investig.

On OnCo: Bendamustine

Paper: Salivary Duct Carcinoma With Rhabdoid and Signet-Ring Cell Features Mimicking Invasive Lobular Carcinoma of the Breast: A Case Report and Review of the Literature.

2026-09-19T00:00:00Z

Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Salivary duct carcinoma.

19 September 2026, Int J Surg Pathol.

On OnCo: Salivary duct carcinoma

Paper: Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.

2026-09-19T00:00:00Z

Published in Int J Hematol on 19 September 2026; matched the OnCo record for Decitabine.

19 September 2026, Int J Hematol.

On OnCo: Decitabine, Quizartinib

Paper: Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

2026-09-19T00:00:00Z

Published in Target Oncol on 19 September 2026; matched the OnCo record for Tucatinib.

19 September 2026, Target Oncol.

On OnCo: Tucatinib

Paper: Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.

2026-09-19T00:00:00Z

Published in Int J Clin Oncol on 19 September 2026; matched the OnCo record for Amrubicin.

19 September 2026, Int J Clin Oncol.

On OnCo: Amrubicin

Paper: Transoral Robotic Surgery (TORS) versus radical radiotherapy following neoadjuvant therapy for oropharyngeal carcinoma: a multicenter, real-world efficacy and safety analysis.

2026-09-19T00:00:00Z

Published in J Robot Surg on 19 September 2026; matched the OnCo record for Transoral robotic surgery.

19 September 2026, J Robot Surg.

On OnCo: Transoral robotic surgery

Paper: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.

2026-09-12T00:00:00Z

Published in N Engl J Med on 12 September 2026; matched the OnCo record for YL201.

12 September 2026, N Engl J Med.

On OnCo: YL201

Paper: [Corrigendum] The interaction between miR‑148a and DNMT1 suppresses cell migration and invasion by reactivating tumor suppressor genes in pancreatic cancer.

2026-09-18T00:00:00Z

Published in Oncol Rep on 18 September 2026; matched the OnCo record for DNMT1.

18 September 2026, Oncol Rep.

On OnCo: DNMT1

Paper: [Update on anal dysplasia and anal cancer].

2026-09-18T00:00:00Z

Published in Dermatologie (Heidelb) on 18 September 2026; matched the OnCo record for Metastatic and recurrent anal squamous cell carcinoma.

18 September 2026, Dermatologie (Heidelb).

On OnCo: Metastatic and recurrent anal squamous cell carcinoma, Retifanlimab

Paper: A canonical role of SMAD4 in safeguarding 3D genome architecture to suppress lung tumorigenesis.

2026-09-18T00:00:00Z

Published in Oncogene on 18 September 2026; matched the OnCo record for Genetically engineered mouse models.

18 September 2026, Oncogene.

On OnCo: Genetically engineered mouse models

Paper: A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer.

2026-09-18T00:00:00Z

Published in Mol Med Rep on 18 September 2026; matched the OnCo record for EGFR-mutated non-small-cell lung cancer.

18 September 2026, Mol Med Rep.

On OnCo: EGFR-mutated non-small-cell lung cancer

Paper: A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

2026-09-18T00:00:00Z

Published in Br J Haematol on 18 September 2026; matched the OnCo record for Avelumab.

18 September 2026, Br J Haematol.

On OnCo: Avelumab

Paper: Acute Myocardial Infarction in Head and Neck Cancer Patients and Survivors: A Population-Based Cohort Study of Patient, Disease, and Treatment Factors.

2026-09-18T00:00:00Z

Published in Clin Oncol (R Coll Radiol) on 18 September 2026; matched the OnCo record for Hypopharyngeal cancer.

18 September 2026, Clin Oncol (R Coll Radiol).

On OnCo: Hypopharyngeal cancer

Paper: Anagrelide remodels the PDE3A-SLFN12 interactome to associate with translation initiation machinery in cancer cell lines.

2026-09-18T00:00:00Z

Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for Anagrelide.

18 September 2026, Mol Cell Proteomics.

On OnCo: Anagrelide

Paper: Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation.

2026-09-18T00:00:00Z

Published in J Clin Pathol on 18 September 2026; matched the OnCo record for Paige Prostate Detect.

18 September 2026, J Clin Pathol.

On OnCo: Paige Prostate Detect

Paper: Beyond Anatomical Resectability: A Hypermetabolic and Highly Aggressive Subtype of Spinal Chordoma Associated with Cancer-Specific Progression.

2026-09-18T00:00:00Z

Published in Spine J on 18 September 2026; matched the OnCo record for Chordoma.

18 September 2026, Spine J.

On OnCo: Chordoma

Paper: Can early 68Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium.

2026-09-18T00:00:00Z

Published in BMJ Open on 18 September 2026; matched the OnCo record for Gallium-68 gozetotide.

18 September 2026, BMJ Open.

On OnCo: Gallium-68 gozetotide

Paper: Carbohydrate-Directed Labeling Probes for UV-Independent Chemoproteomic Profiling of Carbohydrate-Protein Interactions.

2026-09-18T00:00:00Z

Published in Angew Chem Int Ed Engl on 18 September 2026; matched the OnCo record for CD22.

18 September 2026, Angew Chem Int Ed Engl.

On OnCo: CD22

Paper: Chemotherapy Versus Surgery for Stage IIA Nonseminomatous Germ Cell Tumor: A Comparative Cost Utility Analysis.

2026-09-18T00:00:00Z

Published in J Urol on 18 September 2026; matched the OnCo record for Testicular germ cell tumours.

18 September 2026, J Urol.

On OnCo: Testicular germ cell tumours

Paper: Class visualizations and activation atlases for computational pathology.

2026-09-18T00:00:00Z

Published in Cell Rep Med on 18 September 2026; matched the OnCo record for Pathology & radiology foundation models.

18 September 2026, Cell Rep Med.

On OnCo: Pathology & radiology foundation models

Paper: Claudin 18.2 Expression and Outcomes in Resected Gallbladder and Biliary Tract Adenocarcinomas: A Pilot Clinicopathologic Study.

2026-09-18T00:00:00Z

Published in Int J Surg Pathol on 18 September 2026; matched the OnCo record for VENTANA PD-L1 (SP263) Assay.

18 September 2026, Int J Surg Pathol.

On OnCo: VENTANA PD-L1 (SP263) Assay

Paper: Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor-Targeted Agents in Advanced Gastric and Gastroesophageal Adenocarcinoma: A Systematic Review and Meta-analysis.

2026-09-18T00:00:00Z

Published in Am J Clin Oncol on 18 September 2026; matched the OnCo record for Rivoceranib.

18 September 2026, Am J Clin Oncol.

On OnCo: Rivoceranib

Paper: Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial.

2026-09-18T00:00:00Z

Published in Patient on 18 September 2026; matched the OnCo record for Vimseltinib.

18 September 2026, Patient.

On OnCo: Vimseltinib

Paper: Community-Based Skin Cancer Screening and Follow-up Outcomes from a Statewide Outreach Program.

2026-09-18T00:00:00Z

Published in J Am Acad Dermatol on 18 September 2026; matched the OnCo record for Skin cancer screening.

18 September 2026, J Am Acad Dermatol.

On OnCo: Skin cancer screening

Paper: Compartment-specific CD8 infiltration and disease-specific survival in resected ampullary adenocarcinoma.

2026-09-18T00:00:00Z

Published in Cancer Res Commun on 18 September 2026; matched the OnCo record for Ampullary cancer.

18 September 2026, Cancer Res Commun.

On OnCo: Ampullary cancer

Paper: Disseminated Fusarium infection following cladribine chemotherapy for hairy-cell leukaemia.

2026-09-18T00:00:00Z

Published in BMJ Case Rep on 18 September 2026; matched the OnCo record for Cladribine.

18 September 2026, BMJ Case Rep.

On OnCo: Cladribine, Hairy cell leukaemia

Paper: Effect of transcutaneous auricular vagus nerve stimulation on postoperative gastrointestinal dysfunction in patients with gynecological abdominal or pelvic tumors: a study protocol for a prospective, single-center, randomized, controlled clinical trial.

2026-09-18T00:00:00Z

Published in Ann Med on 18 September 2026; matched the OnCo record for Stage III melanoma.

18 September 2026, Ann Med.

On OnCo: Stage III melanoma

Paper: Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen.

2026-09-18T00:00:00Z

Published in Urol Oncol on 18 September 2026; matched the OnCo record for Gemcitabine + cisplatin.

18 September 2026, Urol Oncol.

On OnCo: Gemcitabine + cisplatin, Toripalimab

Paper: Efficacy and safety of proton radiotherapy for progressive or surgically unfavorable adult pilocytic astrocytoma: a single-center experience.

2026-09-18T00:00:00Z

Published in J Neurooncol on 18 September 2026; matched the OnCo record for Paediatric low-grade glioma.

18 September 2026, J Neurooncol.

On OnCo: Paediatric low-grade glioma

Paper: Emerging role of targeted therapy in drug-resistant epilepsy in patients with glioma.

2026-09-18T00:00:00Z

Published in Curr Opin Oncol on 18 September 2026; matched the OnCo record for Vorasidenib.

18 September 2026, Curr Opin Oncol.

On OnCo: Vorasidenib

Paper: Erythematous dorsal plaques in 6 patients with advanced T-cell lymphoma: a clinical variant of mogamulizumab-associated rash.

2026-09-18T00:00:00Z

Published in Actas Dermosifiliogr on 18 September 2026; matched the OnCo record for Mogamulizumab.

18 September 2026, Actas Dermosifiliogr.

On OnCo: Mogamulizumab

Paper: FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer.

2026-09-18T00:00:00Z

Published in BMC Med Imaging on 18 September 2026; matched the OnCo record for Locally advanced cervical cancer.

18 September 2026, BMC Med Imaging.

On OnCo: Locally advanced cervical cancer, Recurrent or metastatic cervical cancer

Paper: Feasibility of prostate offline adaptive radiation therapy using iterative reconstructed CBCT to optimize the ART workflow.

2026-09-18T00:00:00Z

Published in Phys Med on 18 September 2026; matched the OnCo record for MR-guided adaptive radiotherapy.

18 September 2026, Phys Med.

On OnCo: MR-guided adaptive radiotherapy

Paper: Frailty of older patients is not reflected in the melanoma tumor microenvironment and treatment response to immune checkpoint blockade therapy.

2026-09-18T00:00:00Z

Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Imaging mass cytometry.

18 September 2026, J Immunother Cancer.

On OnCo: Imaging mass cytometry

Paper: Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.

2026-09-18T00:00:00Z

Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Ciltacabtagene autoleucel.

18 September 2026, J Immunother Cancer.

On OnCo: Ciltacabtagene autoleucel, Idecabtagene vicleucel

Paper: Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome.

2026-09-18T00:00:00Z

Published in J Comp Eff Res on 18 September 2026; matched the OnCo record for Small intestine cancer.

18 September 2026, J Comp Eff Res.

On OnCo: Small intestine cancer

Paper: Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

2026-09-18T00:00:00Z

Published in Blood Adv on 18 September 2026; matched the OnCo record for Allogeneic stem cell transplantation.

18 September 2026, Blood Adv.

On OnCo: Allogeneic stem cell transplantation, Loncastuximab tesirine

Paper: MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.

2026-09-18T00:00:00Z

Published in Future Oncol on 18 September 2026; matched the OnCo record for Node-positive and metastatic penile cancer.

18 September 2026, Future Oncol.

On OnCo: Node-positive and metastatic penile cancer, Pucotenlimab

Paper: Modulating pseudokinase conformation from the ATP-binding site.

2026-09-18T00:00:00Z

Published in Structure on 18 September 2026; matched the OnCo record for HER3.

18 September 2026, Structure.

On OnCo: HER3

Paper: Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026.

2026-09-18T00:00:00Z

Published in Curr Hematol Malig Rep on 18 September 2026; matched the OnCo record for Ropeginterferon alfa-2b.

18 September 2026, Curr Hematol Malig Rep.

On OnCo: Ropeginterferon alfa-2b

Paper: Molecular targeted therapy for thyroid cancer in Japan: Current status and future perspectives.

2026-09-18T00:00:00Z

Published in Auris Nasus Larynx on 18 September 2026; matched the OnCo record for Companion diagnostics.

18 September 2026, Auris Nasus Larynx.

On OnCo: Companion diagnostics

Paper: Multiparametric Whole-Body MRI Protocols in Contemporary Clinical Practice: Indications, Technical Considerations, and Emerging Applications.

2026-09-18T00:00:00Z

Published in J Comput Assist Tomogr on 18 September 2026; matched the OnCo record for Whole-body MRI.

18 September 2026, J Comput Assist Tomogr.

On OnCo: Whole-body MRI

Paper: NHSL3 knockout modulates sorafenib response, growth, and motility in hepatocellular carcinoma cell models.

2026-09-18T00:00:00Z

Published in Mol Biol Rep on 18 September 2026; matched the OnCo record for CRAF.

18 September 2026, Mol Biol Rep.

On OnCo: CRAF

Paper: Nucleolar METTL16 drives ccRCC tumorigenesis and pazopanib resistance via translational activation of JAG1/Notch signaling pathway.

2026-09-18T00:00:00Z

Published in Drug Resist Updat on 18 September 2026; matched the OnCo record for Pazopanib.

18 September 2026, Drug Resist Updat.

On OnCo: Pazopanib

Issue: OnCo weekly, 2026-09-18

2026-09-18T00:00:00Z

303 changelog entries, 1 upcoming date, 11 publications, 8 corrections.

18 September 2026, OnCo weekly issue.

Paper: Onvansertib-mediated PLK1 inhibition impairs spermatogenesis in the murine testis.

2026-09-18T00:00:00Z

Published in Asian J Androl on 18 September 2026; matched the OnCo record for Onvansertib.

18 September 2026, Asian J Androl.

On OnCo: Onvansertib

Paper: Optimizing the Hinge Length of Chimeric Antigen Receptor with a DdFP-Based Immunological Synapse Biosensor.

2026-09-18T00:00:00Z

Published in ACS Sens on 18 September 2026; matched the OnCo record for Mesothelin.

18 September 2026, ACS Sens.

On OnCo: Mesothelin

Paper: Pemetrexed increases BRCA1 protein stability and sensitizes TNBC cells to radiotherapy.

2026-09-18T00:00:00Z

Published in Oncol Rep on 18 September 2026; matched the OnCo record for Pemetrexed.

18 September 2026, Oncol Rep.

On OnCo: Pemetrexed

Paper: Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential.

2026-09-18T00:00:00Z

Published in J Enzyme Inhib Med Chem on 18 September 2026; matched the OnCo record for PARP.

18 September 2026, J Enzyme Inhib Med Chem.

On OnCo: PARP

Paper: Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study.

2026-09-18T00:00:00Z

Published in Cancer Lett on 18 September 2026; matched the OnCo record for cfDNA fragmentomics.

18 September 2026, Cancer Lett.

On OnCo: cfDNA fragmentomics

Paper: Plasma signals of lung tumor promotion and the ubiquitous challenge of biomarker specificity.

2026-09-18T00:00:00Z

Published in Diagnosis (Berl) on 18 September 2026; matched the OnCo record for CEACAM5.

18 September 2026, Diagnosis (Berl).

On OnCo: CEACAM5

Paper: PRC2 loss in MPNST is accompanied by SWI/SNF complex rewiring and sensitization to SMARCA2/4 and BET inhibition in vivo.

2026-09-18T00:00:00Z

Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for Malignant peripheral nerve sheath tumour.

18 September 2026, Mol Cell Proteomics.

On OnCo: Malignant peripheral nerve sheath tumour

Paper: Pre-operative magnetic resonance imaging for evaluating depth of invasion in oral tongue cancer: Precision and predictive value.

2026-09-18T00:00:00Z

Published in J Formos Med Assoc on 18 September 2026; matched the OnCo record for Oral tongue and floor of mouth cancer.

18 September 2026, J Formos Med Assoc.

On OnCo: Oral tongue and floor of mouth cancer

Paper: Prognostic value of the Nice Cancer Ageing Survival (NCAS) score in older adults with cancer: A retrospective single institutional study.

2026-09-18T00:00:00Z

Published in J Geriatr Oncol on 18 September 2026; matched the OnCo record for Geriatric assessment.

18 September 2026, J Geriatr Oncol.

On OnCo: Geriatric assessment

Paper: Recurrence Patterns of Resected Ampullary Adenocarcinoma and Implications for Multimodal Therapy: A Hidden Genome-Derived Analysis from the Ampullary Cancer Collaborative.

2026-09-18T00:00:00Z

Published in Ann Surg Oncol on 18 September 2026; matched the OnCo record for Ampullary cancer.

18 September 2026, Ann Surg Oncol.

On OnCo: Ampullary cancer

Paper: Retraction Note: Buparlisib induces eukaryotic elongation factor-2 expression to cause treatment failure for lung cancer cells.

2026-09-18T00:00:00Z

Published in Mol Genet Genomics on 18 September 2026; matched the OnCo record for Elongation factor 2.

18 September 2026, Mol Genet Genomics.

On OnCo: Elongation factor 2

Paper: Retraction notice to "Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth" [Biochim. Biophys. Acta (BBA) - Gen. Subj. 1860 (2016) 1961-1972].

2026-09-18T00:00:00Z

Published in Biochim Biophys Acta Gen Subj on 18 September 2026; matched the OnCo record for Smoothened.

18 September 2026, Biochim Biophys Acta Gen Subj.

On OnCo: Smoothened

Paper: Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis.

2026-09-18T00:00:00Z

Published in Curr Probl Cancer on 18 September 2026; matched the OnCo record for Teclistamab.

18 September 2026, Curr Probl Cancer.

On OnCo: Teclistamab

Paper: Systematic Evaluation of Combination Strategies with Rezatapopt in p53 Y220C-Mutant Cancer Models.

2026-09-18T00:00:00Z

Published in Mol Cancer Ther on 18 September 2026; matched the OnCo record for MDM2 inhibitors.

18 September 2026, Mol Cancer Ther.

On OnCo: MDM2 inhibitors

Paper: Targeting KRAS-Mutant Lung Cancers.

2026-09-18T00:00:00Z

Published in J Natl Compr Canc Netw on 18 September 2026; matched the OnCo record for Adagrasib.

18 September 2026, J Natl Compr Canc Netw.

On OnCo: Adagrasib, Daraxonrasib, KRAS G12C-mutant non-small-cell lung cancer, Sotorasib, Zoldonrasib

Paper: Targeting overexpressed tumor cell receptors with radiolabeled molecules: Biological targets, clinical applications, and translational challenges.

2026-09-18T00:00:00Z

Published in Bioorg Chem on 18 September 2026; matched the OnCo record for Somatostatin receptor 2.

18 September 2026, Bioorg Chem.

On OnCo: Somatostatin receptor 2

Paper: Upper- versus lower-extremity synovial sarcoma: distinct surgical pathways and postoperative morbidity in a 24-year cohort.

2026-09-18T00:00:00Z

Published in J Cancer Res Clin Oncol on 18 September 2026; matched the OnCo record for Synovial sarcoma.

18 September 2026, J Cancer Res Clin Oncol.

On OnCo: Synovial sarcoma

Paper: Vagus Nerve Stimulation Exerts Disease-Modifying Effects in Epileptic Rats by Enhancing Hippocampal Adenosine Signalling.

2026-09-18T00:00:00Z

Published in Brain Stimul on 18 September 2026; matched the OnCo record for Pilocarpine.

18 September 2026, Brain Stimul.

On OnCo: Pilocarpine

Paper: Validation of next‑generation sequencing‑derived circulating mRNA variants as potential diagnostic tools in hepatocellular carcinoma and cholangiocarcinoma.

2026-09-18T00:00:00Z

Published in Oncol Rep on 18 September 2026; matched the OnCo record for Interferon alfa-2a/2b.

18 September 2026, Oncol Rep.

On OnCo: Interferon alfa-2a/2b

Paper: Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

2026-09-11T00:00:00Z

Published in Ann Oncol on 11 September 2026; matched the OnCo record for Bispecific ADC.

11 September 2026, Ann Oncol.

On OnCo: Bispecific ADC, Izalontamab brengitecan

Paper: Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

2026-09-11T00:00:00Z

Published in J Clin Oncol on 11 September 2026; matched the OnCo record for HER2 tyrosine kinase inhibitors.

11 September 2026, J Clin Oncol.

On OnCo: HER2 tyrosine kinase inhibitors, Trastuzumab emtansine

Approval: Approval: Camizestrant (US)

2026-09-04T00:00:00Z

Accelerated approval (Etcamah).

4 September 2026, FDA.

On OnCo: Camizestrant, HR-positive / HER2-negative breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Estrogen receptor

Approval: FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

2026-09-04T00:00:00Z

On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.

4 September 2026, FDA.

On OnCo: Camizestrant, Palbociclib, Abemaciclib, Ribociclib, HR-positive / HER2-negative breast cancer

Paper: [Tenosyovial giant cell tumor (TGCT): From the physiopathology to the emergence of new targeted therapies].

2026-09-17T00:00:00Z

Published in Bull Cancer on 17 September 2026; matched the OnCo record for Tenosynovial giant cell tumour.

17 September 2026, Bull Cancer.

On OnCo: Tenosynovial giant cell tumour

Paper: A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax.

2026-09-17T00:00:00Z

Published in Hemasphere on 17 September 2026; matched the OnCo record for Functional (ex vivo) drug testing.

17 September 2026, Hemasphere.

On OnCo: Functional (ex vivo) drug testing

Paper: Acute Myeloid Leukemia With KMT2A Amplification: A TP53-Alteration-Enriched Subgroup Associated With Chromoanagenesis and Poor Prognosis.

2026-09-17T00:00:00Z

Published in Mod Pathol on 17 September 2026; matched the OnCo record for Secondary and therapy-related acute myeloid leukaemia.

17 September 2026, Mod Pathol.

On OnCo: Secondary and therapy-related acute myeloid leukaemia

Paper: Admission low-density lipoprotein cholesterol and early haematoma expansion after spontaneous intracerebral haemorrhage.

2026-09-17T00:00:00Z

Published in Ann Med on 17 September 2026; matched the OnCo record for CT.

17 September 2026, Ann Med.

On OnCo: CT

Paper: ALPHA-1 antitrypsin genotype, sex, and lung cancer: Clinical and molecular characterisation.

2026-09-17T00:00:00Z

Published in Pulmonology on 17 September 2026; matched the OnCo record for EGFR.

17 September 2026, Pulmonology.

On OnCo: EGFR

Paper: An integrated multiomic single-vesicle atlas delineates graft exosome heterogeneity in chronic lung allograft dysfunction.

2026-09-17T00:00:00Z

Published in Signal Transduct Target Ther on 17 September 2026; matched the OnCo record for CD73 / adenosine axis.

17 September 2026, Signal Transduct Target Ther.

On OnCo: CD73 / adenosine axis, G-CSF receptor

Paper: Artificial Intelligence-Driven Precision Bisphosphonate Therapy in Osteoporosis: Mechanisms, Clinical Applications, Risks, and Future Directions.

2026-09-17T00:00:00Z

Published in Orthop Surg on 17 September 2026; matched the OnCo record for Zoledronic acid.

17 September 2026, Orthop Surg.

On OnCo: Zoledronic acid

Paper: Association of body mass index with postoperative pulmonary complications and potential explanatory pathways in paediatric scoliosis correction surgery: a multicentre cohort study.

2026-09-17T00:00:00Z

Published in Ann Med on 17 September 2026; matched the OnCo record for Neuroblastoma.

17 September 2026, Ann Med.

On OnCo: Neuroblastoma

Paper: Biochemical characteristics associated with spironolactone use in hospitalized patients with hypotonic hyponatraemia.

2026-09-17T00:00:00Z

Published in Ann Med on 17 September 2026; matched the OnCo record for EGFR.

17 September 2026, Ann Med.

On OnCo: EGFR

Paper: Change in the incidence of medication-related osteonecrosis of the jaw in lung cancer patients receiving bone modifying agents with immune checkpoint inhibitors.

2026-09-17T00:00:00Z

Published in Lung Cancer on 17 September 2026; matched the OnCo record for Bone-modifying agents.

17 September 2026, Lung Cancer.

On OnCo: Bone-modifying agents

Paper: Characterization of DPYD pharmacogenetic variation in Mexican patients with gastrointestinal malignancies.

2026-09-17T00:00:00Z

Published in Cancer Chemother Pharmacol on 17 September 2026; matched the OnCo record for Thymidylate synthase.

17 September 2026, Cancer Chemother Pharmacol.

On OnCo: Thymidylate synthase

Paper: Clinical activity of platinum rechallenge with nedaplatin plus irinotecan in recurrent cervical cancer following prior platinum-based systemic chemotherapy: a single-center retrospective study.

2026-09-17T00:00:00Z

Published in Int J Clin Oncol on 17 September 2026; matched the OnCo record for Nedaplatin.

17 September 2026, Int J Clin Oncol.

On OnCo: Nedaplatin

Paper: Clinical relevance of antiphosphatidylserine/prothrombin antibodies in antiphospholipid syndrome.

2026-09-17T00:00:00Z

Published in Curr Opin Immunol on 17 September 2026; matched the OnCo record for Acute promyelocytic leukaemia.

17 September 2026, Curr Opin Immunol.

On OnCo: Acute promyelocytic leukaemia

Paper: Clinicopathological and Molecular Insights into ERBB2-altered S100/SOX10-positive Uterine Sarcoma: A Report of 6 Cases.

2026-09-17T00:00:00Z

Published in Mod Pathol on 17 September 2026; matched the OnCo record for HER3.

17 September 2026, Mod Pathol.

On OnCo: HER3

Paper: CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas.

2026-09-17T00:00:00Z

Published in Cancer Chemother Pharmacol on 17 September 2026; matched the OnCo record for Inavolisib.

17 September 2026, Cancer Chemother Pharmacol.

On OnCo: Inavolisib, Ipatasertib, Paediatric high-grade glioma

Paper: Do not stop at the variant: a reversible cause of small-fiber neuropathy symptoms in an ATTRv carrier.

2026-09-17T00:00:00Z

Published in Neurol Sci on 17 September 2026; matched the OnCo record for TSH receptor.

17 September 2026, Neurol Sci.

On OnCo: TSH receptor

Paper: Efficacy of prophylactic pegfilgrastim compared with therapeutic filgrastim for preventing febrile neutropenia during chemotherapy for musculoskeletal tumors: A single-center retrospective study.

2026-09-17T00:00:00Z

Published in J Orthop Sci on 17 September 2026; matched the OnCo record for Pegfilgrastim.

17 September 2026, J Orthop Sci.

On OnCo: Pegfilgrastim

Paper: Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.

2026-09-17T00:00:00Z

Published in Clin Cancer Res on 17 September 2026; matched the OnCo record for EGFR-mutated non-small-cell lung cancer.

17 September 2026, Clin Cancer Res.

On OnCo: EGFR-mutated non-small-cell lung cancer, Savolitinib

Paper: Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer.

2026-09-17T00:00:00Z

Published in Oncologist on 17 September 2026; matched the OnCo record for STEAP1.

17 September 2026, Oncologist.

On OnCo: STEAP1

Paper: Hepatocellular Carcinoma With JAK1 Mutations Harbors Distinct Histologic Features and Specific Mutational Hotspots in an Asian Cohort.

2026-09-17T00:00:00Z

Published in Am J Surg Pathol on 17 September 2026; matched the OnCo record for FRK kinase.

17 September 2026, Am J Surg Pathol.

On OnCo: FRK kinase

Paper: Highly viscous ascites prompting reconsideration of cardiorenal syndrome in a patient with advanced CKD after TAVI.

2026-09-17T00:00:00Z

Published in CEN Case Rep on 17 September 2026; matched the OnCo record for Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei.

17 September 2026, CEN Case Rep.

On OnCo: Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei

Paper: HLX11: A Pertuzumab Biosimilar.

2026-09-17T00:00:00Z

Published in BioDrugs on 17 September 2026; matched the OnCo record for HLX11.

17 September 2026, BioDrugs.

On OnCo: HLX11

Paper: Human Umbilical Cord Mesenchymal Stem Cells Enhance Folliculogenesis and Fertility in Premature Ovarian Failure Mice via Regulating Steroid synthesis.

2026-09-17T00:00:00Z

Published in Stem Cells on 17 September 2026; matched the OnCo record for CYP11A1.

17 September 2026, Stem Cells.

On OnCo: CYP11A1

Paper: Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia.

2026-09-17T00:00:00Z

Published in Oncoimmunology on 17 September 2026; matched the OnCo record for CAR-T cell therapy.

17 September 2026, Oncoimmunology.

On OnCo: CAR-T cell therapy, Immune checkpoint inhibitors, LAG-3, TIGIT blockade, TIGIT, TIM-3

Paper: Impact of early postoperative human chorionic gonadotropin change direction after high-intensity focused ultrasound on ultrasound-guided dilation and curettage outcomes in cesarean scar pregnancy: a retrospective study.

2026-09-17T00:00:00Z

Published in Int J Hyperthermia on 17 September 2026; matched the OnCo record for Focused ultrasound & histotripsy.

17 September 2026, Int J Hyperthermia.

On OnCo: Focused ultrasound & histotripsy

Paper: Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

2026-09-17T00:00:00Z

Published in Haematologica on 17 September 2026; matched the OnCo record for Autologous stem cell transplant.

17 September 2026, Haematologica.

On OnCo: Autologous stem cell transplant, Thalidomide

Paper: Intraoperative or postoperative radiotherapy boost in high-risk breast cancer: a matched-pair analysis.

2026-09-17T00:00:00Z

Published in Strahlenther Onkol on 17 September 2026; matched the OnCo record for Intraoperative radiotherapy.

17 September 2026, Strahlenther Onkol.

On OnCo: Intraoperative radiotherapy

Paper: Mechanistic insights into phosphorylation-driven activation and therapeutic inhibition of human ATR-ATRIP.

2026-09-17T00:00:00Z

Published in Nat Struct Mol Biol on 17 September 2026; matched the OnCo record for Ceralasertib.

17 September 2026, Nat Struct Mol Biol.

On OnCo: Ceralasertib

Paper: Metabolic Improvement and Weight Reduction After Large Endoscopic Submucosal Dissection Including the Papilla for Duodenal Adenoma: A Case Report.

2026-09-17T00:00:00Z

Published in DEN Open on 17 September 2026; matched the OnCo record for Iobenguane I-131.

17 September 2026, DEN Open.

On OnCo: Iobenguane I-131

Issue: OnCo weekly, 2026-09-17

2026-09-17T00:00:00Z

147 changelog entries, 1 upcoming date, 14 publications, 91 corrections.

17 September 2026, OnCo weekly issue.

Paper: Organoids Serve as Viable In Vitro Model for Functional Precision Medicine for Mesonephric-Like Adenocarcinoma of the Ovary.

2026-09-17T00:00:00Z

Published in JCO Precis Oncol on 17 September 2026; matched the OnCo record for Functional (ex vivo) drug testing.

17 September 2026, JCO Precis Oncol.

On OnCo: Functional (ex vivo) drug testing

Paper: Post-Hoc Long-Read Sequencing Links Leukemic Mutation Status to Single-Cell Transcriptomes.

2026-09-17T00:00:00Z

Published in Eur J Haematol on 17 September 2026; matched the OnCo record for Long-read sequencing.

17 September 2026, Eur J Haematol.

On OnCo: Long-read sequencing

Paper: Precision Medicine for Somatic Mutation-Driven Vascular Anomalies.

2026-09-17T00:00:00Z

Published in Br J Dermatol on 17 September 2026; matched the OnCo record for MEK1/2.

17 September 2026, Br J Dermatol.

On OnCo: MEK1/2

Paper: Primary Large B-Cell Lymphomas of Immune-Privileged Sites With IRF4 Rearrangement: Clinicopathological and Molecular Characterization.

2026-09-17T00:00:00Z

Published in Mod Pathol on 17 September 2026; matched the OnCo record for CD79b.

17 September 2026, Mod Pathol.

On OnCo: CD79b

Proposal: Proposed approval: Givinostat

2026-09-17T00:00:00Z

openFDA has a label for "Givinostat".

17 September 2026, FDA.

On OnCo: Givinostat

Proposal: Proposed regional approval row: Alemtuzumab

2026-09-17T00:00:00Z

EMA register: MabCampath (alemtuzumab) Withdrawn, 2001-07-06.

17 September 2026, EMA.

On OnCo: Alemtuzumab

Proposal: Proposed regional approval row: Anagrelide

2026-09-17T00:00:00Z

EMA register: Xagrid (anagrelide) Authorised, 2004-11-15.

17 September 2026, EMA.

On OnCo: Anagrelide

Proposal: Proposed regional approval row: Aprepitant

2026-09-17T00:00:00Z

EMA register: Emend (aprepitant) Authorised, 2003-11-11.

17 September 2026, EMA.

On OnCo: Aprepitant

Proposal: Proposed regional approval row: Bexarotene

2026-09-17T00:00:00Z

EMA register: Targretin (bexarotene) Authorised, 2001-03-29.

17 September 2026, EMA.

On OnCo: Bexarotene

Proposal: Proposed regional approval row: Busulfan

2026-09-17T00:00:00Z

EMA register: Busilvex (busulfan) Withdrawn, 2003-07-09.

17 September 2026, EMA.

On OnCo: Busulfan

Proposal: Proposed regional approval row: Capecitabine

2026-09-17T00:00:00Z

EMA register: Xeloda (capecitabine) Authorised, 2001-02-02.

17 September 2026, EMA.

On OnCo: Capecitabine

Proposal: Proposed regional approval row: Capmatinib

2026-09-17T00:00:00Z

EMA register: Tabrecta (capmatinib) Authorised, 2022-06-20.

17 September 2026, EMA.

On OnCo: Capmatinib

Proposal: Proposed regional approval row: Carmustine

2026-09-17T00:00:00Z

EMA register: Carmustine medac (previously Carmustine Obvius) (carmustine) Authorised, 2018-07-18.

17 September 2026, EMA.

On OnCo: Carmustine

Proposal: Proposed regional approval row: Catumaxomab

2026-09-17T00:00:00Z

EMA register: Korjuny (catumaxomab) Authorised, 2025-02-10.

17 September 2026, EMA.

On OnCo: Catumaxomab

Proposal: Proposed regional approval row: Clofarabine

2026-09-17T00:00:00Z

EMA register: Evoltra (clofarabine) Authorised, 2006-05-29.

17 September 2026, EMA.

On OnCo: Clofarabine

Proposal: Proposed regional approval row: Cytarabine

2026-09-17T00:00:00Z

EMA register: DepoCyte (cytarabine) Withdrawn, 2001-07-11.

17 September 2026, EMA.

On OnCo: Cytarabine

Proposal: Proposed regional approval row: Dabrafenib

2026-09-17T00:00:00Z

EMA register: Tafinlar (dabrafenib) Authorised, 2013-08-26.

17 September 2026, EMA.

On OnCo: Dabrafenib

Proposal: Proposed regional approval row: Darbepoetin alfa

2026-09-17T00:00:00Z

EMA register: Aranesp (darbepoetin alfa) Authorised, 2001-06-08.

17 September 2026, EMA.

On OnCo: Darbepoetin alfa

Proposal: Proposed regional approval row: Daunorubicin

2026-09-17T00:00:00Z

EMA register: Vyxeos liposomal (previously Vyxeos) (daunorubicin;cytarabine) Authorised, 2018-08-23.

17 September 2026, EMA.

On OnCo: Daunorubicin

Proposal: Proposed regional approval row: Decitabine

2026-09-17T00:00:00Z

EMA register: Dacogen (decitabine) Authorised, 2012-09-20.

17 September 2026, EMA.

On OnCo: Decitabine

Proposal: Proposed regional approval row: Denosumab

2026-09-17T00:00:00Z

EMA register: Prolia (denosumab) Authorised, 2010-05-26.

17 September 2026, EMA.

On OnCo: Denosumab

Proposal: Proposed regional approval row: Dexamethasone

2026-09-17T00:00:00Z

EMA register: Neofordex (dexamethasone) Authorised, 2016-03-16.

17 September 2026, EMA.

On OnCo: Dexamethasone

Proposal: Proposed regional approval row: Dorocubicel

2026-09-17T00:00:00Z

EMA register: Zemcelpro (allogeneic umbilical cord-derived CD34- cells, non-expanded;dorocubicel) Authorised (conditional), 2025-08-25.

17 September 2026, EMA.

On OnCo: Dorocubicel

Proposal: Proposed regional approval row: Efbemalenograstim alfa

2026-09-17T00:00:00Z

EMA register: Ryzneuta (efbemalenograstim alfa) Authorised, 2024-03-21.

17 September 2026, EMA.

On OnCo: Efbemalenograstim alfa

Paper: Redefining Care for IDH-Mutant Low-Grade Gliomas: Clinical Implications of the INDIGO Trial and Updated Guidelines.

2026-09-17T00:00:00Z

Published in Clin Med (Lond) on 17 September 2026; matched the OnCo record for Vorasidenib.

17 September 2026, Clin Med (Lond).

On OnCo: Vorasidenib

Paper: Rigorous, transparent and inconclusive: what Europe's first joint clinical assessment reveals about a framework trying to serve everyone.

2026-09-17T00:00:00Z

Published in J Comp Eff Res on 17 September 2026; matched the OnCo record for Tovorafenib.

17 September 2026, J Comp Eff Res.

On OnCo: Tovorafenib

Paper: Silent pheochromocytoma presenting as refractory hyperglycemia without classic adrenergic symptoms.

2026-09-17T00:00:00Z

Published in JCEM Case Rep on 17 September 2026; matched the OnCo record for Pheochromocytoma and paraganglioma.

17 September 2026, JCEM Case Rep.

On OnCo: Pheochromocytoma and paraganglioma

Paper: Spontaneous lytic reactivation drives a persistent B cell-vector pathway for epithelial dissemination of the Epstein-Barr virus.

2026-09-17T00:00:00Z

Published in Cell Rep on 17 September 2026; matched the OnCo record for EphA2 receptor.

17 September 2026, Cell Rep.

On OnCo: EphA2 receptor

Paper: Surgical debulking and electrochemotherapy, including a tetrapolar single-needle electrode, are associated with clinical benefit in dogs with intranasal tumors.

2026-09-17T00:00:00Z

Published in J Am Vet Med Assoc on 17 September 2026; matched the OnCo record for Electrochemotherapy.

17 September 2026, J Am Vet Med Assoc.

On OnCo: Electrochemotherapy

Paper: Surgical resection of a liver metastasis from an ovarian granulosa cell tumor mimicking a simple hepatic cyst.

2026-09-17T00:00:00Z

Published in Clin J Gastroenterol on 17 September 2026; matched the OnCo record for Adult granulosa cell tumour of the ovary.

17 September 2026, Clin J Gastroenterol.

On OnCo: Adult granulosa cell tumour of the ovary

Paper: Targeting tryptophan hydroxylase 1 restricts growth and suppresses plasticity in neuroendocrine prostate cancer.

2026-09-17T00:00:00Z

Published in J Clin Invest on 17 September 2026; matched the OnCo record for Neuroendocrine and small-cell prostate cancer.

17 September 2026, J Clin Invest.

On OnCo: Neuroendocrine and small-cell prostate cancer, Tryptophan hydroxylase 1

Paper: To eat, or not to eat… dietary patterns and the clinical recognition of insulinoma: a case report.

2026-09-17T00:00:00Z

Published in J Basic Clin Physiol Pharmacol on 17 September 2026; matched the OnCo record for Diazoxide.

17 September 2026, J Basic Clin Physiol Pharmacol.

On OnCo: Diazoxide

Paper: Tumor FAK supports fibrillar collagen expression in ovarian cancer ascites.

2026-09-17T00:00:00Z

Published in Matrix Biol on 17 September 2026; matched the OnCo record for IN10018.

17 September 2026, Matrix Biol.

On OnCo: IN10018

Paper: Wilms tumor with rare spinal metastasis treated with surgery and chemotherapy: A case report.

2026-09-17T00:00:00Z

Published in J Int Med Res on 17 September 2026; matched the OnCo record for Wilms tumour.

17 September 2026, J Int Med Res.

On OnCo: Wilms tumour

Paper: X‑ray FLASH RT inhibits lung cancer bone metastasis via activating CD4⁺ T-cell‑mediated antitumor immunity with modulation of Th17 cell response.

2026-09-17T00:00:00Z

Published in Oncoimmunology on 17 September 2026; matched the OnCo record for FLASH radiotherapy.

17 September 2026, Oncoimmunology.

On OnCo: FLASH radiotherapy

Paper: A clinically-oriented foundation model for intraoperative pathology.

2026-09-10T00:00:00Z

Published in Nat Med on 10 September 2026; matched the OnCo record for Pathology & radiology foundation models.

10 September 2026, Nat Med.

On OnCo: Pathology & radiology foundation models

Paper: Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.

2026-09-10T00:00:00Z

Published in J Clin Oncol on 10 September 2026; matched the OnCo record for Iberdomide.

10 September 2026, J Clin Oncol.

On OnCo: Iberdomide

Paper: [Management of venous thromboembolism in children with acute lymphoblastic leukemia: Recommendations from the harmonization workshops of the Leukemia Committee of the French Society for Childhood Cancer (SFCE)].

2026-09-16T00:00:00Z

Published in Bull Cancer on 16 September 2026; matched the OnCo record for Asparaginase.

16 September 2026, Bull Cancer.

On OnCo: Asparaginase

Paper: EML4::RET, a novel transcript fusion in papillary thyroid cancer.

2026-09-16T00:00:00Z

Published in JCEM Case Rep on 16 September 2026; matched the OnCo record for Comprehensive genomic profiling.

16 September 2026, JCEM Case Rep.

On OnCo: Comprehensive genomic profiling, NTRK

Paper: A Broad-Spectrum Tumor-Penetrating Peptide WKASC: Design, Screening, and Platform Development for Cancer Therapy.

2026-09-16T00:00:00Z

Published in Small on 16 September 2026; matched the OnCo record for Methyl aminolevulinate.

16 September 2026, Small.

On OnCo: Methyl aminolevulinate

Paper: A decade of survival in recurrent nonfunctioning oncocytic adrenocortical carcinoma in a young Filipina.

2026-09-16T00:00:00Z

Published in JCEM Case Rep on 16 September 2026; matched the OnCo record for Advanced and metastatic adrenocortical carcinoma.

16 September 2026, JCEM Case Rep.

On OnCo: Advanced and metastatic adrenocortical carcinoma, Mitotane

Paper: A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901).

2026-09-16T00:00:00Z

Published in Gastric Cancer on 16 September 2026; matched the OnCo record for Ramucirumab.

16 September 2026, Gastric Cancer.

On OnCo: Ramucirumab

Paper: A Systematic Pipeline for Evaluating Factors Affecting Radar-Based Microwave Breast Imaging Quality.

2026-09-16T00:00:00Z

Published in Biomed Phys Eng Express on 16 September 2026; matched the OnCo record for RaDaR.

16 September 2026, Biomed Phys Eng Express.

On OnCo: RaDaR

Paper: Advances in the Targeted Therapy for PIK3CA-Related Overgrowth Spectrum (PROS): From Molecular Mechanisms to Clinical Translation.

2026-09-16T00:00:00Z

Published in Pediatr Blood Cancer on 16 September 2026; matched the OnCo record for Alpelisib.

16 September 2026, Pediatr Blood Cancer.

On OnCo: Alpelisib

Paper: Analysis of MTHFR C677T polymorphism in elderly Iranian women from Bushehr.

2026-09-16T00:00:00Z

Published in J Diabetes Metab Disord on 16 September 2026; matched the OnCo record for DNA methylation profiling.

16 September 2026, J Diabetes Metab Disord.

On OnCo: DNA methylation profiling

Paper: Can Chemoradiotherapy Expand Immune Checkpoint Blockade Responsiveness in Mismatch Repair-Proficient Rectal Cancer?

2026-09-16T00:00:00Z

Published in Ann Gastroenterol Surg on 16 September 2026; matched the OnCo record for Mismatch-repair deficient (MSI-high) colorectal cancer.

16 September 2026, Ann Gastroenterol Surg.

On OnCo: Mismatch-repair deficient (MSI-high) colorectal cancer

Paper: Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.

2026-09-16T00:00:00Z

Published in Commun Med (Lond) on 16 September 2026; matched the OnCo record for Emavusertib.

16 September 2026, Commun Med (Lond).

On OnCo: Emavusertib

Paper: Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity.

2026-09-16T00:00:00Z

Published in Adv Sci (Weinh) on 16 September 2026; matched the OnCo record for Immunocytokines.

16 September 2026, Adv Sci (Weinh).

On OnCo: Immunocytokines

Paper: Concomitant parathyroid hormone-secreting oncocytic adrenocortical carcinoma and parathyroid adenoma.

2026-09-16T00:00:00Z

Published in JCEM Case Rep on 16 September 2026; matched the OnCo record for Mitotane.

16 September 2026, JCEM Case Rep.

On OnCo: Mitotane

Paper: Conserved hepatic RNA signatures across multiple cohorts reveal novel mechanistic clues for advanced fibrosis in human MASLD.

2026-09-16T00:00:00Z

Published in Hepatol Commun on 16 September 2026; matched the OnCo record for CDH6.

16 September 2026, Hepatol Commun.

On OnCo: CDH6, PDGFRA

Paper: Conversion from calcineurin inhibitor to ruxolitinib as GVHD prophylaxis during patients with transplant-associated thrombotic microangiopathy.

2026-09-16T00:00:00Z

Published in Transplant Cell Ther on 16 September 2026; matched the OnCo record for Indolent and smouldering systemic mastocytosis.

16 September 2026, Transplant Cell Ther.

On OnCo: Indolent and smouldering systemic mastocytosis

Paper: Corrigendum to "Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6"[Clinical Lymphoma Myeloma and Leukemia 26 (2026) 317-327].

2026-09-16T00:00:00Z

Published in Clin Lymphoma Myeloma Leuk on 16 September 2026; matched the OnCo record for Epcoritamab.

16 September 2026, Clin Lymphoma Myeloma Leuk.

On OnCo: Epcoritamab

Paper: Culture-Proven Haemophilus influenzae Endophthalmitis After Intravitreal Topotecan for Retinoblastoma.

2026-09-16T00:00:00Z

Published in J Vitreoretin Dis on 16 September 2026; matched the OnCo record for Melphalan.

16 September 2026, J Vitreoretin Dis.

On OnCo: Melphalan

Paper: Cutaneous Toxicities of Anti-GPRC5D Bispecific Antibodies for Multiple Myeloma: Retrospective Study.

2026-09-16T00:00:00Z

Published in J Dermatol on 16 September 2026; matched the OnCo record for GPRC5D.

16 September 2026, J Dermatol.

On OnCo: GPRC5D, Talquetamab

Paper: Effect of phenylephrine versus ephedrine on the incidence of postoperative delirium in elderly patients undergoing non-cardiac and non-neurosurgical procedures: protocol for a multicentre, double-blind, randomized, controlled trial.

2026-09-16T00:00:00Z

Published in Ann Med on 16 September 2026; matched the OnCo record for Stage III melanoma.

16 September 2026, Ann Med.

On OnCo: Stage III melanoma

Paper: Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.

2026-09-16T00:00:00Z

Published in Breast Cancer Res Treat on 16 September 2026; matched the OnCo record for CellSearch circulating tumour cell count.

16 September 2026, Breast Cancer Res Treat.

On OnCo: CellSearch circulating tumour cell count, Eribulin

Paper: Engineered probiotics for tumor-targeted combination chemoimmunotherapy.

2026-09-16T00:00:00Z

Published in Sci Transl Med on 16 September 2026; matched the OnCo record for Cytokines & engineered cytokines.

16 September 2026, Sci Transl Med.

On OnCo: Cytokines & engineered cytokines

Paper: Epithelial tumor suppressor deletion promotes neuroendocrine differentiation in bladder cancer and reveals homoharringtonine as a candidate vulnerability.

2026-09-16T00:00:00Z

Published in Oncogene on 16 September 2026; matched the OnCo record for Genetically engineered mouse models.

16 September 2026, Oncogene.

On OnCo: Genetically engineered mouse models, Omacetaxine mepesuccinate

Paper: Erythropoietin impacts immune adaptation through myeloid-cell programming.

2026-09-16T00:00:00Z

Published in Trends Immunol on 16 September 2026; matched the OnCo record for Erythropoietin receptor.

16 September 2026, Trends Immunol.

On OnCo: Erythropoietin receptor

Paper: Evaluation of a rapid-release mitomycin C-loaded porous microcapsule formulation (MitoCap) in a human urothelium-tumour model.

2026-09-16T00:00:00Z

Published in Int J Pharm on 16 September 2026; matched the OnCo record for Mitomycin C.

16 September 2026, Int J Pharm.

On OnCo: Mitomycin C

Paper: Evolutionary genomics, tumor dynamics, and mathematical modeling of cancer progression: Implications for precision oncology.

2026-09-16T00:00:00Z

Published in Infect Genet Evol on 16 September 2026; matched the OnCo record for Adaptive therapy.

16 September 2026, Infect Genet Evol.

On OnCo: Adaptive therapy, Mathematical models of cancer

Paper: Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.

2026-09-16T00:00:00Z

Published in Gynecol Oncol on 16 September 2026; matched the OnCo record for Avutometinib + defactinib.

16 September 2026, Gynecol Oncol.

On OnCo: Avutometinib + defactinib

Paper: Managing capivasertib-induced hyperglycemia: a report of 3 cases.

2026-09-16T00:00:00Z

Published in JCEM Case Rep on 16 September 2026; matched the OnCo record for Alpelisib.

16 September 2026, JCEM Case Rep.

On OnCo: Alpelisib

Paper: Medication-related osteonecrosis of the external auditory canal and treatment with teriparatide.

2026-09-16T00:00:00Z

Published in JCEM Case Rep on 16 September 2026; matched the OnCo record for Denosumab.

16 September 2026, JCEM Case Rep.

On OnCo: Denosumab

Issue: OnCo weekly, 2026-09-16

2026-09-16T00:00:00Z

17 changelog entries, 1 upcoming date, 20 publications, 89 corrections.

16 September 2026, OnCo weekly issue.

Paper: Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin.

2026-09-16T00:00:00Z

Published in Target Oncol on 16 September 2026; matched the OnCo record for Inotuzumab ozogamicin.

16 September 2026, Target Oncol.

On OnCo: Inotuzumab ozogamicin

Paper: Pattern of Failure in Nasopharyngeal Carcinoma After Radiotherapy in a Low-Incidence Population: A DAHANCA Study.

2026-09-16T00:00:00Z

Published in Head Neck on 16 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.

16 September 2026, Head Neck.

On OnCo: Early-stage classical Hodgkin lymphoma

Paper: Paving the way for more accessible cancer care in low-income countries with optimization.

2026-09-16T00:00:00Z

Published in Health Care Manag Sci on 16 September 2026; matched the OnCo record for Mathematical models of cancer.

16 September 2026, Health Care Manag Sci.

On OnCo: Mathematical models of cancer

Paper: Penpulimab: A next-generation Fc-engineered PD-1 inhibitor in cancer immunotherapy.

2026-09-16T00:00:00Z

Published in Crit Rev Oncol Hematol on 16 September 2026; matched the OnCo record for Penpulimab.

16 September 2026, Crit Rev Oncol Hematol.

On OnCo: Penpulimab

Paper: Phenotype-driven cascade screening in a Syrian family with clinically consistent multiple endocrine neoplasia type 2A.

2026-09-16T00:00:00Z

Published in JCEM Case Rep on 16 September 2026; matched the OnCo record for Medullary thyroid cancer.

16 September 2026, JCEM Case Rep.

On OnCo: Medullary thyroid cancer, Pheochromocytoma and paraganglioma

Paper: Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations.

2026-09-16T00:00:00Z

Published in Future Oncol on 16 September 2026; matched the OnCo record for Adagrasib.

16 September 2026, Future Oncol.

On OnCo: Adagrasib, KRYSTAL-12, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall

Paper: Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma.

2026-09-16T00:00:00Z

Published in Future Oncol on 16 September 2026; matched the OnCo record for Axicabtagene ciloleucel.

16 September 2026, Future Oncol.

On OnCo: Axicabtagene ciloleucel

Paper: Prolactinoma assessment and management: an international multidisciplinary cross-sectional survey of current practice.

2026-09-16T00:00:00Z

Published in Pituitary on 16 September 2026; matched the OnCo record for Cabergoline.

16 September 2026, Pituitary.

On OnCo: Cabergoline

Paper: Radiotherapy in Thoracic NUT Carcinoma: A Pooled Analysis of Long-term Survivors and Clinical Outcome Heterogeneity.

2026-09-16T00:00:00Z

Published in Arch Bronconeumol on 16 September 2026; matched the OnCo record for NUT carcinoma.

16 September 2026, Arch Bronconeumol.

On OnCo: NUT carcinoma

Paper: Repurposing Anticancer Drugs in Parkinson's Treatment: Molecular Pathways Driving Neuroprotection and Therapeutic Advancement.

2026-09-16T00:00:00Z

Published in Mol Neurobiol on 16 September 2026; matched the OnCo record for Ixazomib.

16 September 2026, Mol Neurobiol.

On OnCo: Ixazomib, Nilotinib

Paper: Sex Differences in Complications and Outcomes of Wilms Tumor: Is There a Role for Sex-based Approaches in Nephroblastoma Management?

2026-09-16T00:00:00Z

Published in J Pediatr Hematol Oncol on 16 September 2026; matched the OnCo record for Wilms tumour.

16 September 2026, J Pediatr Hematol Oncol.

On OnCo: Wilms tumour

Paper: Sirolimus Dose Reduction After Belumosudil Initiation in Pediatric and Young Adult Patients With Chronic Graft-Versus-Host-Disease.

2026-09-16T00:00:00Z

Published in Pediatr Blood Cancer on 16 September 2026; matched the OnCo record for Belumosudil.

16 September 2026, Pediatr Blood Cancer.

On OnCo: Belumosudil

Paper: Sonogenetics Nanomedicine Activates the cGAS-STING Pathway for Immunotherapy of Triple-Negative Breast Cancer.

2026-09-16T00:00:00Z

Published in Adv Sci (Weinh) on 16 September 2026; matched the OnCo record for HER3.

16 September 2026, Adv Sci (Weinh).

On OnCo: HER3

Paper: Surgical considerations in post-programmed cell death-1 therapy for cutaneous squamous cell carcinoma.

2026-09-16T00:00:00Z

Published in Proc (Bayl Univ Med Cent) on 16 September 2026; matched the OnCo record for Cemiplimab.

16 September 2026, Proc (Bayl Univ Med Cent).

On OnCo: Cemiplimab

Paper: Targeting EGFR-Mutant Non-Small Cell Lung Cancer in Asia: An Update on Monotherapy and Combination Therapy With EGFR Inhibitors.

2026-09-16T00:00:00Z

Published in Respirology on 16 September 2026; matched the OnCo record for EGFR-mutated non-small-cell lung cancer.

16 September 2026, Respirology.

On OnCo: EGFR-mutated non-small-cell lung cancer

Paper: Tumor-homing peptides in precision oncology.

2026-09-16T00:00:00Z

Published in J Control Release on 16 September 2026; matched the OnCo record for Melphalan flufenamide.

16 September 2026, J Control Release.

On OnCo: Melphalan flufenamide, Melphalan

Paper: Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis.

2026-09-16T00:00:00Z

Published in ESMO Open on 16 September 2026; matched the OnCo record for Tislelizumab.

16 September 2026, ESMO Open.

On OnCo: Tislelizumab, Zolbetuximab

Paper: LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.

2026-09-09T00:00:00Z

Published in J Clin Oncol on 9 September 2026; matched the OnCo record for CD79b.

9 September 2026, J Clin Oncol.

On OnCo: CD79b, Polatuzumab vedotin

Paper: Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia - Authors' reply.

2026-09-09T00:00:00Z

Published in Lancet Haematol on 9 September 2026; matched the OnCo record for Inotuzumab ozogamicin.

9 September 2026, Lancet Haematol.

On OnCo: Inotuzumab ozogamicin

Paper: Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia.

2026-09-09T00:00:00Z

Published in Lancet Haematol on 9 September 2026; matched the OnCo record for Inotuzumab ozogamicin.

9 September 2026, Lancet Haematol.

On OnCo: Inotuzumab ozogamicin

Paper: TRI-611, a selective, brain-penetrant molecular glue degrader of ALK.

2026-09-09T00:00:00Z

Published in Nature on 9 September 2026; matched the OnCo record for TRI-611.

9 September 2026, Nature.

On OnCo: TRI-611

Paper: [Development of an artificial intelligence-assisted diagnostic model for malignant head and neck tumors based on endoscopic images].

2026-09-15T00:00:00Z

Published in Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi on 15 September 2026; matched the OnCo record for Hypopharyngeal cancer.

15 September 2026, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.

On OnCo: Hypopharyngeal cancer

Paper: Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval.

2026-09-15T00:00:00Z

Published in Expert Rev Hematol on 15 September 2026; matched the OnCo record for Pacritinib.

15 September 2026, Expert Rev Hematol.

On OnCo: Pacritinib

Paper: Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.

2026-09-15T00:00:00Z

Published in Clin Cancer Res on 15 September 2026; matched the OnCo record for Amivantamab.

15 September 2026, Clin Cancer Res.

On OnCo: Amivantamab, HPV-positive oropharyngeal cancer

Paper: Barriers for general practitioners in post-stroke follow-up within a fragmented healthcare system in Sweden - a focus group study.

2026-09-15T00:00:00Z

Published in Eur J Gen Pract on 15 September 2026; matched the OnCo record for Undifferentiated pleomorphic sarcoma.

15 September 2026, Eur J Gen Pract.

On OnCo: Undifferentiated pleomorphic sarcoma

Paper: Biomarker-guided treatment selection in metastatic colorectal cancer: A critical review of established and emerging therapies.

2026-09-15T00:00:00Z

Published in Crit Rev Oncol Hematol on 15 September 2026; matched the OnCo record for Amivantamab.

15 September 2026, Crit Rev Oncol Hematol.

On OnCo: Amivantamab, Encorafenib, Tucatinib, Zanzalintinib

Paper: Bronchial stump re-resection for carcinoid tumor recurrence after left pneumonectomy: Case report.

2026-09-15T00:00:00Z

Published in Turk Gogus Kalp Damar Cerrahisi Derg on 15 September 2026; matched the OnCo record for Lung neuroendocrine tumours.

15 September 2026, Turk Gogus Kalp Damar Cerrahisi Derg.

On OnCo: Lung neuroendocrine tumours

Paper: Chromophobe Renal Cell Carcinoma With Multimodal Imaging Features: A Case Report.

2026-09-15T00:00:00Z

Published in Australas J Ultrasound Med on 15 September 2026; matched the OnCo record for Chromophobe renal cell carcinoma.

15 September 2026, Australas J Ultrasound Med.

On OnCo: Chromophobe renal cell carcinoma

Paper: Comparative Transcriptomic and Immune Profiling Reveals a Shared Molecular Identity Between Clear Cell Odontogenic Carcinoma and Hyalinizing Clear Cell Carcinoma.

2026-09-15T00:00:00Z

Published in Mol Cancer Res on 15 September 2026; matched the OnCo record for Folate receptor alpha.

15 September 2026, Mol Cancer Res.

On OnCo: Folate receptor alpha, Mesothelin

Paper: Cooccurrence of Homologous Recombination Deficiency and Mismatch Repair Deficiency in Colorectal Cancer.

2026-09-15T00:00:00Z

Published in MedComm (2020) on 15 September 2026; matched the OnCo record for HRD & BRCA testing.

15 September 2026, MedComm (2020).

On OnCo: HRD & BRCA testing

Paper: Customizable host and viral transcript enrichment using CRISPR-Cas9 long-read sequencing for characterization of low-to-moderate abundance isoforms.

2026-09-15T00:00:00Z

Published in NAR Genom Bioinform on 15 September 2026; matched the OnCo record for Long-read sequencing.

15 September 2026, NAR Genom Bioinform.

On OnCo: Long-read sequencing

Paper: Design, calibration, and preliminary testing of an additive-manufactured Raman spectrometer for skin cancer screening.

2026-09-15T00:00:00Z

Published in Spectrochim Acta A Mol Biomol Spectrosc on 15 September 2026; matched the OnCo record for Skin cancer screening.

15 September 2026, Spectrochim Acta A Mol Biomol Spectrosc.

On OnCo: Skin cancer screening

Paper: Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.

2026-09-15T00:00:00Z

Published in Ann Hematol on 15 September 2026; matched the OnCo record for Ciltacabtagene autoleucel.

15 September 2026, Ann Hematol.

On OnCo: Ciltacabtagene autoleucel, Idecabtagene vicleucel

Paper: Efficacy and Safety of Co-Ablation Combined With Aintilimab for Metastatic Melanoma to the Liver (CryoCheck-001): A Phase II Trial.

2026-09-15T00:00:00Z

Published in MedComm (2020) on 15 September 2026; matched the OnCo record for Sintilimab.

15 September 2026, MedComm (2020).

On OnCo: Sintilimab

Paper: Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment.

2026-09-15T00:00:00Z

Published in Am J Hematol on 15 September 2026; matched the OnCo record for BCL-2 inhibitors.

15 September 2026, Am J Hematol.

On OnCo: BCL-2 inhibitors, CD123

Paper: High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy.

2026-09-15T00:00:00Z

Published in Blood Res on 15 September 2026; matched the OnCo record for Ponatinib.

15 September 2026, Blood Res.

On OnCo: Ponatinib

Paper: Impact of time from diagnosis to endoscopic resection on clinical outcomes in early gastric cancer.

2026-09-15T00:00:00Z

Published in Ann Med on 15 September 2026; matched the OnCo record for Endoscopic resection.

15 September 2026, Ann Med.

On OnCo: Endoscopic resection

Paper: Induction FLOT Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in the Treatment of Lower Esophageal and Proximal Gastric Adenocarcinoma: A Phase II, Single-Arm Clinical Trial.

2026-09-15T00:00:00Z

Published in J Gastrointest Cancer on 15 September 2026; matched the OnCo record for FLOT.

15 September 2026, J Gastrointest Cancer.

On OnCo: FLOT

Paper: Intestinal Serotonergic Vagal Signaling as a Mediator of Microbiota-Induced Hypertension.

2026-09-15T00:00:00Z

Published on 15 September 2026 after first appearing as a preprint; matched Iobenguane I-131.

15 September 2026.

On OnCo: Iobenguane I-131

Paper: Joint Learning of Drug-Drug Combination and Drug-Drug Interaction via Coupled Tensor-Tensor Factorization with Side Information.

2026-09-15T00:00:00Z

Published on 15 September 2026 after first appearing as a preprint; matched Iobenguane I-131.

15 September 2026.

On OnCo: Iobenguane I-131

Paper: Multicenter study of cladribine in relapsing-remitting multiple sclerosis in patients over 50 years.

2026-09-15T00:00:00Z

Published in Farm Hosp on 15 September 2026; matched the OnCo record for Cladribine.

15 September 2026, Farm Hosp.

On OnCo: Cladribine

Paper: Myeloma-Associated Sporadic Late-Onset Nemaline Myopathy, Successfully Treated with Daratumumab Based Induction and Autologous Stem Cell Transplantation: A Case Report.

2026-09-15T00:00:00Z

Published in EJHaem on 15 September 2026; matched the OnCo record for Melphalan.

15 September 2026, EJHaem.

On OnCo: Melphalan

Paper: Nab-paclitaxel fused with the de novo designed receptor binder exhibits enhanced tumor targeting and therapeutic efficacy.

2026-09-15T00:00:00Z

Published in J Control Release on 15 September 2026; matched the OnCo record for De novo designed protein binders.

15 September 2026, J Control Release.

On OnCo: De novo designed protein binders

Issue: OnCo weekly, 2026-09-15

2026-09-15T00:00:00Z

14 changelog entries, 1 upcoming date, 20 publications, 89 corrections.

15 September 2026, OnCo weekly issue.

Paper: Oral Manifestations and Management of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.

2026-09-15T00:00:00Z

Published in J Stomatol Oral Maxillofac Surg on 15 September 2026; matched the OnCo record for Tucidinostat.

15 September 2026, J Stomatol Oral Maxillofac Surg.

On OnCo: Tucidinostat

Paper: Pangenome analysis reveals both niche-specific "specialists" and microbial "side hustlers" in colorectal cancer microbiomes.

2026-09-15T00:00:00Z

Published in Gut Microbes on 15 September 2026; matched the OnCo record for Chemoprevention & risk-reducing surgery.

15 September 2026, Gut Microbes.

On OnCo: Chemoprevention & risk-reducing surgery

Paper: Paraneoplastic Neurological Syndrome in a Patient with Limited-stage Small-cell Lung Cancer Receiving Durvalumab Maintenance after Concurrent Chemoradiotherapy: A Case Report.

2026-09-15T00:00:00Z

Published in Intern Med on 15 September 2026; matched the OnCo record for Limited-stage small-cell lung cancer.

15 September 2026, Intern Med.

On OnCo: Limited-stage small-cell lung cancer

Paper: Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy.

2026-09-15T00:00:00Z

Published in Urol Oncol on 15 September 2026; matched the OnCo record for Hexaminolevulinate.

15 September 2026, Urol Oncol.

On OnCo: Hexaminolevulinate

Paper: Phosphoproteomics identifies the DYRK1B protein kinase as a regulator of processing bodies.

2026-09-15T00:00:00Z

Published on 15 September 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics.

15 September 2026.

On OnCo: Proteomics & phosphoproteomics

Paper: Post-Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management.

2026-09-15T00:00:00Z

Published in MedComm (2020) on 15 September 2026; matched the OnCo record for Post-transplant lymphoproliferative disorder.

15 September 2026, MedComm (2020).

On OnCo: Post-transplant lymphoproliferative disorder

Paper: Prognostic implications of HPV and TP53 status in early-stage vulvar squamous cell carcinoma.

2026-09-15T00:00:00Z

Published in Gynecol Oncol on 15 September 2026; matched the OnCo record for HPV-independent vulvar squamous cell carcinoma.

15 September 2026, Gynecol Oncol.

On OnCo: HPV-independent vulvar squamous cell carcinoma

Paper: Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia.

2026-09-15T00:00:00Z

Published in Br J Haematol on 15 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

15 September 2026, Br J Haematol.

On OnCo: Acute lymphoblastic leukaemia

Paper: Resident immune cell neighborhoods associate with protein kinase pRIPK3 and fatty acid ligase FACL4 expression during cell injury in ANCA associated vasculitis and lupus nephritis.

2026-09-15T00:00:00Z

Published in Kidney Int on 15 September 2026; matched the OnCo record for Imaging mass cytometry.

15 September 2026, Kidney Int.

On OnCo: Imaging mass cytometry

Paper: Reverse genetics in humanized mice reveals CARD8-mediated pyroptosis causing pancytopenia in human DPP9 deficiency.

2026-09-15T00:00:00Z

Published on 15 September 2026 after first appearing as a preprint; matched Iobenguane I-131.

15 September 2026.

On OnCo: Iobenguane I-131

Paper: Synergistic chitosan nanoparticles loaded with baricitinib for the management of persistent chemotherapy-induced alopecia.

2026-09-15T00:00:00Z

Published in Int J Biol Macromol on 15 September 2026; matched the OnCo record for Scalp cooling.

15 September 2026, Int J Biol Macromol.

On OnCo: Scalp cooling

Paper: Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system.

2026-09-15T00:00:00Z

Published in Hematology on 15 September 2026; matched the OnCo record for BCMA.

15 September 2026, Hematology.

On OnCo: BCMA, Bispecific antibodies, CD3, MCLA-129, Multiple myeloma, T-cell engagers, Teclistamab

Paper: The Terminator-A Blood Test for Early Detection of 50 Cancers.

2026-09-15T00:00:00Z

Published in Public Health Chall on 15 September 2026; matched the OnCo record for Galleri.

15 September 2026, Public Health Chall.

On OnCo: Galleri, Multi-cancer early detection

Paper: VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications.

2026-09-15T00:00:00Z

Published in Med Oncol on 15 September 2026; matched the OnCo record for VISTA.

15 September 2026, Med Oncol.

On OnCo: VISTA

Paper: 177Lu-trastuzumab radionuclide therapy: a promising strategy for trastuzumab-resistant brain metastases in HER2+ breast cancer.

2026-09-14T00:00:00Z

Published in Mol Biomed on 14 September 2026; matched the OnCo record for Immuno-PET.

14 September 2026, Mol Biomed.

On OnCo: Immuno-PET

Paper: A novel multiomics machine learning signature identifies rapid progression in clinically low risk prostate cancer.

2026-09-14T00:00:00Z

Published in NPJ Digit Med on 14 September 2026; matched the OnCo record for Localised prostate cancer, very low and low risk.

14 September 2026, NPJ Digit Med.

On OnCo: Localised prostate cancer, very low and low risk

Paper: Acinar Cell Carcinoma of the Pancreas: A Three Case Series and Literature Review.

2026-09-14T00:00:00Z

Published in Niger Med J on 14 September 2026; matched the OnCo record for Pancreatic acinar cell carcinoma.

14 September 2026, Niger Med J.

On OnCo: Pancreatic acinar cell carcinoma

Paper: Belumosudil Demonstrates Steroid-Sparing, Safety, and Efficacy in Pediatric Chronic Graft-Versus-Host Disease.

2026-09-14T00:00:00Z

Published in Transplant Cell Ther on 14 September 2026; matched the OnCo record for Belumosudil.

14 September 2026, Transplant Cell Ther.

On OnCo: Belumosudil

Paper: Brain dose burden is associated with treatment-related lymphopenia in IDH-wildtype glioblastoma: dosimetric determinants and prognostic impact.

2026-09-14T00:00:00Z

Published on 14 September 2026 after first appearing as a preprint; matched Temozolomide.

14 September 2026.

On OnCo: Temozolomide

Paper: Brief Communication: LSD1 Inhibition Enhances Susceptibility of Primary AML Cells for NK Cell-Mediated Killing.

2026-09-14T00:00:00Z

Published in J Immunother on 14 September 2026; matched the OnCo record for Bomedemstat.

14 September 2026, J Immunother.

On OnCo: Bomedemstat, LSD1 inhibitors

Paper: CD73 and PD-L1 expression in WHO grade 1 and grade 2 meningiomas: an exploratory analysis of purinergic and immune-related profiles.

2026-09-14T00:00:00Z

Published in J Neurooncol on 14 September 2026; matched the OnCo record for CD73 / adenosine axis.

14 September 2026, J Neurooncol.

On OnCo: CD73 / adenosine axis

Paper: Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.

2026-09-14T00:00:00Z

Published in J Egypt Natl Canc Inst on 14 September 2026; matched the OnCo record for Befotertinib.

14 September 2026, J Egypt Natl Canc Inst.

On OnCo: Befotertinib

Paper: Comparative Prognostic Value of Pre- and Post-Induction Chemotherapy Tumor Volumes in Locoregionally Advanced Nasopharyngeal Carcinoma.

2026-09-14T00:00:00Z

Published in Cancer Res Treat on 14 September 2026; matched the OnCo record for Locoregionally advanced nasopharyngeal carcinoma.

14 September 2026, Cancer Res Treat.

On OnCo: Locoregionally advanced nasopharyngeal carcinoma

Paper: Correlation of 68Ga-PSMA-11 PET/CT biodistribution with PSMA expression by immunohistochemistry in patients with HCC: A pilot prospective monocentric study.

2026-09-14T00:00:00Z

Published in Eur J Nucl Med Mol Imaging on 14 September 2026; matched the OnCo record for Gallium-68 gozetotide.

14 September 2026, Eur J Nucl Med Mol Imaging.

On OnCo: Gallium-68 gozetotide

Paper: Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer.

2026-09-14T00:00:00Z

Published in Int J Hyperthermia on 14 September 2026; matched the OnCo record for Androgen deprivation & AR pathway inhibitors.

14 September 2026, Int J Hyperthermia.

On OnCo: Androgen deprivation & AR pathway inhibitors, Degarelix, Multiparametric prostate MRI

Paper: eGFP tagged ZnO nanoparticles from glioblastoma targeting ferroptosis and MRP1 in head and neck squamous cell carcinoma.

2026-09-14T00:00:00Z

Published in Discov Nano on 14 September 2026; matched the OnCo record for Hypopharyngeal cancer.

14 September 2026, Discov Nano.

On OnCo: Hypopharyngeal cancer

Paper: From sensitivity gain to clinical decisions: total-body and long-axial-field-of-view PET/CT for diagnosis and image-based management in oncology and systemic disease.

2026-09-14T00:00:00Z

Published in Ann Nucl Med on 14 September 2026; matched the OnCo record for Immuno-PET.

14 September 2026, Ann Nucl Med.

On OnCo: Immuno-PET, Radioembolisation

Paper: HPV-associated Cancer Diagnoses and Mortality in People With HIV in South Carolina During the Antiretroviral Therapy Era.

2026-09-14T00:00:00Z

Published in J Low Genit Tract Dis on 14 September 2026; matched the OnCo record for Vulvar cancer.

14 September 2026, J Low Genit Tract Dis.

On OnCo: Vulvar cancer

Paper: Hypersensitivity to PEG-Asparaginase and Desensitization Strategies in Pediatric Acute Lymphoblastic Leukemia: A Narrative Review.

2026-09-14T00:00:00Z

Published in Acta Med Acad on 14 September 2026; matched the OnCo record for Asparaginase.

14 September 2026, Acta Med Acad.

On OnCo: Asparaginase

Paper: Image-guided high-dose-rate brachytherapy after short-course external beam radiotherapy for elderly/frail rectal cancer patients.

2026-09-14T00:00:00Z

Published in Strahlenther Onkol on 14 September 2026; matched the OnCo record for High-dose-rate brachytherapy.

14 September 2026, Strahlenther Onkol.

On OnCo: High-dose-rate brachytherapy

Paper: Integrative oncology consultation and patient referral to complementary therapies: results from the prospective study THERAC.

2026-09-14T00:00:00Z

Published in Support Care Cancer on 14 September 2026; matched the OnCo record for Aromatherapy.

14 September 2026, Support Care Cancer.

On OnCo: Aromatherapy

Paper: Long-term quality of life and physical functioning after curative local treatment of colorectal metastases in older patients.

2026-09-14T00:00:00Z

Published in Eur J Surg Oncol on 14 September 2026; matched the OnCo record for G8 geriatric screening tool.

14 September 2026, Eur J Surg Oncol.

On OnCo: G8 geriatric screening tool

Paper: Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.

2026-09-14T00:00:00Z

Published in Lung Cancer on 14 September 2026; found by the roadmap watch for FLAURA2.

14 September 2026, Lung Cancer.

On OnCo: FLAURA2, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall

Paper: Molecular Subtyping of Biliary Tract Neuroendocrine Carcinomas: Clinicopathological Features and Prognostic Implications.

2026-09-14T00:00:00Z

Published in Am J Surg Pathol on 14 September 2026; matched the OnCo record for Ampullary cancer.

14 September 2026, Am J Surg Pathol.

On OnCo: Ampullary cancer

Paper: Multicancer Detection Tests for Population-Wide Screening of Asymptomatic Individuals: A Systematic Review.

2026-09-14T00:00:00Z

Published in JCO Oncol Pract on 14 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.

14 September 2026, JCO Oncol Pract.

On OnCo: Early-stage classical Hodgkin lymphoma

Paper: New Annular, Indurated Plaques During Mogamulizumab Therapy in Cutaneous T-Cell Lymphoma: A Clinicopathologic Pitfall.

2026-09-14T00:00:00Z

Published in J Cutan Pathol on 14 September 2026; matched the OnCo record for Mogamulizumab.

14 September 2026, J Cutan Pathol.

On OnCo: Mogamulizumab

Paper: Occupational trauma and probable PTSD among sworn and civilian police employees.

2026-09-14T00:00:00Z

Published in Eur J Psychotraumatol on 14 September 2026; matched the OnCo record for Plasma cell leukaemia.

14 September 2026, Eur J Psychotraumatol.

On OnCo: Plasma cell leukaemia

Paper: Paediatric Primary Intracranial Tumours: A 14-year Clinicopathologic Study in North-Central Nigeria.

2026-09-14T00:00:00Z

Published in Niger Med J on 14 September 2026; matched the OnCo record for Paediatric low-grade glioma.

14 September 2026, Niger Med J.

On OnCo: Paediatric low-grade glioma

Paper: Paired oral clinical specimens reveal the underlying ecology supporting the emergence of inflammophilic microbiome communities.

2026-09-14T00:00:00Z

Published on 14 September 2026 after first appearing as a preprint; matched Azacitidine, Decitabine + cedazuridine and Iobenguane I-131.

14 September 2026.

On OnCo: Azacitidine, Decitabine + cedazuridine, Iobenguane I-131

Paper: Pharmacokinetics and efficacy of tank water-administered BRAF-inhibitor dabrafenib in a zebrafish melanoma model.

2026-09-14T00:00:00Z

Published in Dis Model Mech on 14 September 2026; matched the OnCo record for BRAF V600-mutant melanoma.

14 September 2026, Dis Model Mech.

On OnCo: BRAF V600-mutant melanoma

Paper: PSMA1, PSMA5, and PSMB2 serve as prognostic biomarkers and are correlated with tumor-infiltrating leukocytes in HCC.

2026-09-14T00:00:00Z

Published in Epigenetics on 14 September 2026; matched the OnCo record for Atlas.

14 September 2026, Epigenetics.

On OnCo: Atlas, DNA methylation profiling, Proteasome

Paper: Resistance mechanisms and therapeutic strategies after menin inhibitor failure in acute myeloid leukemia.

2026-09-14T00:00:00Z

Published in Expert Rev Hematol on 14 September 2026; matched the OnCo record for Revumenib.

14 September 2026, Expert Rev Hematol.

On OnCo: Revumenib, Ziftomenib

Paper: RETRACTED: Salem et al. Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model. Cancers 2020, 12, 2854.

2026-09-14T00:00:00Z

Published in Cancers (Basel) on 14 September 2026; matched the OnCo record for EphA2 receptor.

14 September 2026, Cancers (Basel).

On OnCo: EphA2 receptor

Paper: Reversing sarcopenia with megestrol acetate ameliorates systemic inflammation and improves survival in NSCLC.

2026-09-14T00:00:00Z

Published in Transl Oncol on 14 September 2026; matched the OnCo record for Progestins.

14 September 2026, Transl Oncol.

On OnCo: Progestins, Megestrol acetate

Paper: Songwriting in Medical Music Therapy in Pediatric Palliative Care: Case-Based Clinical Insight from Music Therapy Practice.

2026-09-14T00:00:00Z

Published in J Palliat Med on 14 September 2026; matched the OnCo record for Burkitt lymphoma.

14 September 2026, J Palliat Med.

On OnCo: Burkitt lymphoma

Paper: Syndromic primary hyperparathyroidism.

2026-09-14T00:00:00Z

Published in J Visc Surg on 14 September 2026; matched the OnCo record for Parathyroid carcinoma.

14 September 2026, J Visc Surg.

On OnCo: Parathyroid carcinoma

Paper: Synergistic effects of hypericin-mediated photodynamic therapy and low-dose cisplatin on cervical cancer cells.

2026-09-14T00:00:00Z

Published in J Photochem Photobiol B on 14 September 2026; matched the OnCo record for Synthetic hypericin.

14 September 2026, J Photochem Photobiol B.

On OnCo: Synthetic hypericin

Paper: Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

2026-09-14T00:00:00Z

Published in Leukemia on 14 September 2026; matched the OnCo record for CD7.

14 September 2026, Leukemia.

On OnCo: CD7

Paper: The machine-learning classifier ALLCatchR2 identifies 20 T-ALL subtypes across cohorts and age groups.

2026-09-14T00:00:00Z

Published on 14 September 2026 after first appearing as a preprint; matched IDH1 / IDH2 and DNA methyltransferase 3A.

14 September 2026.

On OnCo: IDH1 / IDH2, DNA methyltransferase 3A

Paper: The Nova Protocol: a comprehensive multimodal longitudinal study among civilian survivors of a mass trauma event.

2026-09-14T00:00:00Z

Published in Eur J Psychotraumatol on 14 September 2026; matched the OnCo record for Plasma cell leukaemia.

14 September 2026, Eur J Psychotraumatol.

On OnCo: Plasma cell leukaemia

Paper: Two Blastic Plasmacytoid Dendritic Cell Neoplasms treated with the CD123-targeted agent Tagraxofusp presenting divergent outcomes.

2026-09-14T00:00:00Z

Published in J Dtsch Dermatol Ges on 14 September 2026; matched the OnCo record for CD123.

14 September 2026, J Dtsch Dermatol Ges.

On OnCo: CD123

Paper: Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer.

2026-09-14T00:00:00Z

Published in Neoplasia on 14 September 2026; matched the OnCo record for Capmatinib.

14 September 2026, Neoplasia.

On OnCo: Capmatinib, Tepotinib

Paper: Uterine Carcinosarcoma: Mutational Profiling of p53-Abnormal Tumors and Its Association with Histologic Subtypes and Survival in an Underserved Population.

2026-09-14T00:00:00Z

Published in Int J Gynecol Pathol on 14 September 2026; matched the OnCo record for Uterine carcinosarcoma.

14 September 2026, Int J Gynecol Pathol.

On OnCo: Uterine carcinosarcoma

Paper: Biological and Medicinal Aspects of Peptides and Sugar-Based Boron-Containing Compounds.

2026-09-13T00:00:00Z

Published in Handb Exp Pharmacol on 13 September 2026; matched the OnCo record for Ixazomib.

13 September 2026, Handb Exp Pharmacol.

On OnCo: Ixazomib

Paper: Chromosome 17p deletion in aplastic anaemia with paroxysmal nocturnal haemoglobinuria clone: a diagnostic challenge.

2026-09-13T00:00:00Z

Published in J Hematop on 13 September 2026; matched the OnCo record for Romiplostim.

13 September 2026, J Hematop.

On OnCo: Romiplostim

Paper: Comparative Outcomes of Transoral Robotic Surgery Versus Open Surgery in Head and Neck Cancer: A Systematic Review and Meta-Analysis.

2026-09-13T00:00:00Z

Published in Cureus on 13 September 2026; matched the OnCo record for Transoral robotic surgery.

13 September 2026, Cureus.

On OnCo: Transoral robotic surgery

Paper: Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

2026-09-13T00:00:00Z

Published on 13 September 2026 after first appearing as a preprint; matched Cytotoxic chemotherapy and Vincristine.

13 September 2026.

On OnCo: Cytotoxic chemotherapy, Vincristine

Paper: Patient-derived 3D organotypic co-cultures as a long-term ex vivo model for pleomorphic adenoma of the parotid gland.

2026-09-13T00:00:00Z

Published in Sci Rep on 13 September 2026; matched the OnCo record for Somatostatin receptor 2.

13 September 2026, Sci Rep.

On OnCo: Somatostatin receptor 2

Paper: Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials.

2026-09-13T00:00:00Z

Published in Cancer Treat Rev on 13 September 2026; matched the OnCo record for Goserelin / leuprolide.

13 September 2026, Cancer Treat Rev.

On OnCo: Goserelin / leuprolide, Oral SERDs

Paper: Assessing methodological differences in estimating exposure to intimate-partner violence against women in Brazil: a multi-source observational analysis.

2026-09-12T00:00:00Z

Published in Lancet Reg Health Am on 12 September 2026; matched the OnCo record for Logic-gated therapeutics.

12 September 2026, Lancet Reg Health Am.

On OnCo: Logic-gated therapeutics

Paper: C-X-C Motif Chemokine Receptor 4 (CXCR4)-Targeted Biologically Guided Proton Spatially Fractionated Radiotherapy for Bulky Limited-Stage Small Cell Lung Cancer.

2026-09-12T00:00:00Z

Published in Precis Radiat Oncol on 12 September 2026; matched the OnCo record for Limited-stage small-cell lung cancer.

12 September 2026, Precis Radiat Oncol.

On OnCo: Limited-stage small-cell lung cancer

Paper: Development and internal validation of a prediction model for early anastomotic leak after minimally invasive esophagectomy: a prospective cohort study.

2026-09-12T00:00:00Z

Published in Ann Med on 12 September 2026; matched the OnCo record for Cytarabine + anthracycline.

12 September 2026, Ann Med.

On OnCo: Cytarabine + anthracycline

Paper: Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide-HLA complex.

2026-09-12T00:00:00Z

Published in MAbs on 12 September 2026; matched the OnCo record for Bispecific antibodies.

12 September 2026, MAbs.

On OnCo: Bispecific antibodies, MCLA-129

Paper: Divergent c-MYC Expression Patterns in NET and NEC: Insights from a Multicentre Cohort of 1380 Neuroendocrine Neoplasms.

2026-09-12T00:00:00Z

Published in Endocr Pathol on 12 September 2026; matched the OnCo record for Grade 3 well-differentiated neuroendocrine tumour.

12 September 2026, Endocr Pathol.

On OnCo: Grade 3 well-differentiated neuroendocrine tumour

Paper: Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance.

2026-09-12T00:00:00Z

Published in J Immunother Cancer on 12 September 2026; matched the OnCo record for Cytokines & engineered cytokines.

12 September 2026, J Immunother Cancer.

On OnCo: Cytokines & engineered cytokines

Paper: Factors affecting time-to-disposition at a district hospital emergency centre in Cape Town, South Africa.

2026-09-12T00:00:00Z

Published in Afr J Emerg Med on 12 September 2026; matched the OnCo record for Neuroblastoma.

12 September 2026, Afr J Emerg Med.

On OnCo: Neuroblastoma

Paper: Hepatic stellate cells promote structural and functional remodeling of three-dimensional hepatocellular carcinoma coculture spheroids.

2026-09-12T00:00:00Z

Published on 12 September 2026 after first appearing as a preprint; matched Sorafenib and Iobenguane I-131.

12 September 2026.

On OnCo: Sorafenib, Iobenguane I-131

Paper: High levels of nitric oxide and peroxynitrite with protein nitration: a new therapeutic target for gliomas.

2026-09-12T00:00:00Z

Published in Med Gas Res on 12 September 2026; matched the OnCo record for Immune checkpoint inhibitors.

12 September 2026, Med Gas Res.

On OnCo: Immune checkpoint inhibitors

Paper: Immune Checkpoint Inhibition in Locally Advanced, Recurrent, and Metastatic Cutaneous Squamous Cell Carcinoma.

2026-09-12T00:00:00Z

Published in Clin Dermatol on 12 September 2026; matched the OnCo record for Cemiplimab.

12 September 2026, Clin Dermatol.

On OnCo: Cemiplimab, Cosibelimab

Paper: Inferred functional microbiome features are associated with clinical trajectories of low-grade cervical lesions.

2026-09-12T00:00:00Z

Published on 12 September 2026 after first appearing as a preprint; matched State.

12 September 2026.

On OnCo: State

Paper: International Western Radiation Therapy Guidelines Applicability in Low- and Middle-Income Countries for Cervical Cancer Management: A Comparative Survey Example from South and North Border of the Mediterranean Area Countries.

2026-09-12T00:00:00Z

Published in Adv Radiat Oncol on 12 September 2026; matched the OnCo record for Brachytherapy.

12 September 2026, Adv Radiat Oncol.

On OnCo: Brachytherapy, Cervical cancer, CT, MRI, PET, Volumetric modulated arc therapy

Paper: Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion.

2026-09-12T00:00:00Z

Published in Target Oncol on 12 September 2026; matched the OnCo record for Capmatinib.

12 September 2026, Target Oncol.

On OnCo: Capmatinib, Tepotinib

Paper: Mechanism of Qilu Buxue granules in alleviating chemotherapy-induced leukopenia: Insights from network pharmacology, integrated omics, and experimental validation.

2026-09-12T00:00:00Z

Published in J Ethnopharmacol on 12 September 2026; matched the OnCo record for PI3K delta.

12 September 2026, J Ethnopharmacol.

On OnCo: PI3K delta

Paper: MRI-based radiomics analysis and machine learning in the differentiation of endometriomas from hemorrhagic ovarian cysts.

2026-09-12T00:00:00Z

Published in Eur J Radiol Open on 12 September 2026; matched the OnCo record for Radiomics.

12 September 2026, Eur J Radiol Open.

On OnCo: Radiomics

Paper: MRI-Guided SBRT Boost for Patients With Locally Advanced Cervical Cancer Who Are Unsuitable for Standard of Care Image-Guided Brachytherapy.

2026-09-12T00:00:00Z

Published in J Med Imaging Radiat Oncol on 12 September 2026; matched the OnCo record for Locally advanced cervical cancer.

12 September 2026, J Med Imaging Radiat Oncol.

On OnCo: Locally advanced cervical cancer

Paper: Multimodality imaging localization of a giant functional parathyroid adenoma in a young fitness trainer with delayed recognition of hypercalcemia: A case report.

2026-09-12T00:00:00Z

Published in Radiol Case Rep on 12 September 2026; matched the OnCo record for FDG PET.

12 September 2026, Radiol Case Rep.

On OnCo: FDG PET, Fludeoxyglucose F-18, PET/CT

Paper: Navigating rural challenges and promoting posttraumatic growth via expressive writing: a qualitative study among rural breast cancer survivors.

2026-09-12T00:00:00Z

Published on 12 September 2026 after first appearing as a preprint; matched Iobenguane I-131.

12 September 2026.

On OnCo: Iobenguane I-131

Paper: Nucleic Acid Turnover and Lipid Remodeling Distinguish T Cell Activation and Exhaustion States via Label-Free Raman Spectroscopy.

2026-09-12T00:00:00Z

Published on 12 September 2026 after first appearing as a preprint; matched State.

12 September 2026.

On OnCo: State

Paper: Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1.

2026-09-12T00:00:00Z

Published in MAbs on 12 September 2026; matched the OnCo record for Antibody-drug conjugate.

12 September 2026, MAbs.

On OnCo: Antibody-drug conjugate, Bispecific ADC, Bispecific antibodies, Ifinatamab deruxtecan, MCLA-129, Patient-derived xenografts, Topoisomerase-I inhibitors, Zilovertamab vedotin

Paper: Pulse-resolved spatial dosimetry of ultra-high dose rate electron FLASH beams using optical imaging.

2026-09-12T00:00:00Z

Published in Phys Med on 12 September 2026; matched the OnCo record for FLASH radiotherapy.

12 September 2026, Phys Med.

On OnCo: FLASH radiotherapy

Paper: Racial and ethnic survival disparities in primary liver cancer in the United States: a National Cancer Database propensity score-matched study.

2026-09-12T00:00:00Z

Published in Hepat Oncol on 12 September 2026; matched the OnCo record for Cytotoxic chemotherapy.

12 September 2026, Hepat Oncol.

On OnCo: Cytotoxic chemotherapy

Paper: Robotic versus laparoscopic gastrectomy with splenic hilar lymph node dissection: short-term outcomes from a propensity score-matched study.

2026-09-12T00:00:00Z

Published on 12 September 2026 after first appearing as a preprint; matched Robotic & minimally invasive surgery and Cytotoxic chemotherapy.

12 September 2026.

On OnCo: Robotic & minimally invasive surgery, Cytotoxic chemotherapy

Paper: Single-cell transcriptomic atlas of the human fetal uveal tract reveals heterogeneity in melanocyte populations.

2026-09-12T00:00:00Z

Published in iScience on 12 September 2026; matched the OnCo record for Multiplex immunofluorescence.

12 September 2026, iScience.

On OnCo: Multiplex immunofluorescence

Paper: Targeted AAV gene therapy for neuroblastoma via direct capsid-antibody coupling.

2026-09-12T00:00:00Z

Published in EMBO Mol Med on 12 September 2026; matched the OnCo record for GD2.

12 September 2026, EMBO Mol Med.

On OnCo: GD2

Paper: Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.

2026-09-12T00:00:00Z

Published in Endocr J on 12 September 2026; matched the OnCo record for Pasireotide.

12 September 2026, Endocr J.

On OnCo: Pasireotide

Paper: Using patient iPSC-derived retinal pigment epithelium to evaluate differential susceptibility to MEK inhibitor-associated retinopathy.

2026-09-12T00:00:00Z

Published in Exp Eye Res on 12 September 2026; matched the OnCo record for Selumetinib.

12 September 2026, Exp Eye Res.

On OnCo: Selumetinib

Paper: 'Methodological considerations regarding propensity score matching and interpretation of oncologic outcomes in ultrasound-guided versus CT-guided microwave ablation for liver metastases'.

2026-09-11T00:00:00Z

Published in Int J Hyperthermia on 11 September 2026; matched the OnCo record for Thermal ablation.

11 September 2026, Int J Hyperthermia.

On OnCo: Thermal ablation

Paper: 3D-printed PCL scaffold coated with chitosan-hyaluronic acid hydrogel loaded with NGF-overexpressing UiPSC-derived neural crest cells restores erectile function via cavernous nerve regeneration.

2026-09-11T00:00:00Z

Published in Bioact Mater on 11 September 2026; matched the OnCo record for Plasma cell leukaemia.

11 September 2026, Bioact Mater.

On OnCo: Plasma cell leukaemia

Paper: 5-Iodotubercidin inhibits Epithelial to Mesenchymal Transition by inhibiting IKK/NFκB-dependent gene expression.

2026-09-11T00:00:00Z

Published on 11 September 2026 after first appearing as a preprint; matched Small-molecule kinase inhibitors.

11 September 2026.

On OnCo: Small-molecule kinase inhibitors

Paper: 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.

2026-09-11T00:00:00Z

Published in Eur J Cancer on 11 September 2026; matched the OnCo record for MammaPrint.

11 September 2026, Eur J Cancer.

On OnCo: MammaPrint

Paper: A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples.

2026-09-11T00:00:00Z

Published in Epigenetics on 11 September 2026; matched the OnCo record for HER2.

11 September 2026, Epigenetics.

On OnCo: HER2, PDGFRA, Triple-negative breast cancer, DNA methylation profiling

Paper: A Novel Intraoperative Peripheral Nerve Surgery Navigation Technique Using Radar Reflector Localization: Case Series.

2026-09-11T00:00:00Z

Published in Oper Neurosurg on 11 September 2026; matched the OnCo record for RaDaR.

11 September 2026, Oper Neurosurg.

On OnCo: RaDaR

Paper: A novel pipeline for the validation of manganese chelators for the treatment of manganese overload.

2026-09-11T00:00:00Z

Published on 11 September 2026 after first appearing as a preprint; matched Azacitidine and Decitabine + cedazuridine.

11 September 2026.

On OnCo: Azacitidine, Decitabine + cedazuridine

Paper: A Review of Modern Therapies and New Innovations in the Treatment of Cutaneous Graft-versus-Host Disease.

2026-09-11T00:00:00Z

Published in Dermatol Ther (Heidelb) on 11 September 2026; matched the OnCo record for Belumosudil.

11 September 2026, Dermatol Ther (Heidelb).

On OnCo: Belumosudil, Methoxsalen

Paper: Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

2026-09-11T00:00:00Z

Published in Biochim Biophys Acta Rev Cancer on 11 September 2026; matched the OnCo record for Necitumumab.

11 September 2026, Biochim Biophys Acta Rev Cancer.

On OnCo: Necitumumab

Paper: Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study.

2026-09-11T00:00:00Z

Published in Hepatol Int on 11 September 2026; matched the OnCo record for Early hepatocellular carcinoma.

11 September 2026, Hepatol Int.

On OnCo: Early hepatocellular carcinoma, Intermediate hepatocellular carcinoma

Paper: Association Between Castration-resistant Prostate Cancer Progression Patterns and Survival Outcomes in Metastatic Castration-sensitive Prostate Cancer: A Post Hoc Analysis of the TITAN Trial.

2026-09-11T00:00:00Z

Published in Eur Urol Focus on 11 September 2026; matched the OnCo record for Apalutamide.

11 September 2026, Eur Urol Focus.

On OnCo: Apalutamide, TITAN

Paper: Association between patient-reported symptoms and clinical outcomes in R/R CLL.

2026-09-11T00:00:00Z

Published in Blood Adv on 11 September 2026; matched the OnCo record for Zanubrutinib.

11 September 2026, Blood Adv.

On OnCo: Zanubrutinib

Paper: Cancer treatment alters mutant selection in normal esophagus.

2026-09-11T00:00:00Z

Published in Nat Genet on 11 September 2026; matched the OnCo record for FLOT.

11 September 2026, Nat Genet.

On OnCo: FLOT

Paper: Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

2026-09-11T00:00:00Z

Published in J Gynecol Oncol on 11 September 2026; matched the OnCo record for HER3.

11 September 2026, J Gynecol Oncol.

On OnCo: HER3

Paper: Clinical Insights and Therapeutic Strategies for Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Case Report with Literature Review.

2026-09-11T00:00:00Z

Published in Curr Med Imaging on 11 September 2026; matched the OnCo record for Tislelizumab.

11 September 2026, Curr Med Imaging.

On OnCo: Tislelizumab

Paper: Comparative analysis of platinum nanoparticles interactions with Mitomycin C and its activated metabolite.

2026-09-11T00:00:00Z

Published in Biomed Pharmacother on 11 September 2026; matched the OnCo record for Mitomycin C.

11 September 2026, Biomed Pharmacother.

On OnCo: Mitomycin C

Paper: Corrigendum to "Computational screening of Sophora flavescens phytochemicals as potential aromatase inhibitors: Molecular docking, ADMET, Network pharmacology, Molecular dynamics simulation, and DFT studies" [Pharmaceutic. Sci. Adv. 4 (2026) 100108].

2026-09-11T00:00:00Z

Published in Pharm Sci Adv on 11 September 2026; matched the OnCo record for Aromatase.

11 September 2026, Pharm Sci Adv.

On OnCo: Aromatase

Paper: Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial.

2026-09-11T00:00:00Z

Published in Value Health on 11 September 2026; matched the OnCo record for Ciltacabtagene autoleucel.

11 September 2026, Value Health.

On OnCo: Ciltacabtagene autoleucel

Paper: Creating reference data for early hospital outbreak detection algorithms from experts' ratings.

2026-09-11T00:00:00Z

Published in J Hosp Infect on 11 September 2026; matched the OnCo record for Altretamine.

11 September 2026, J Hosp Infect.

On OnCo: Altretamine

Paper: Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort.

2026-09-11T00:00:00Z

Published in ESMO Open on 11 September 2026; matched the OnCo record for Eribulin.

11 September 2026, ESMO Open.

On OnCo: Eribulin

Paper: Design, synthesis, molecular docking and anticancer activity of novel N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives.

2026-09-11T00:00:00Z

Published in RSC Adv on 11 September 2026; matched the OnCo record for Asciminib.

11 September 2026, RSC Adv.

On OnCo: Asciminib

Paper: Detection of androgen receptor (AR) splice variants across diverse prostatic and non-prostatic tumor types using the TruSight Oncology 500 (TSO500) assay.

2026-09-11T00:00:00Z

Published in Hum Pathol on 11 September 2026; matched the OnCo record for Adult granulosa cell tumour of the ovary.

11 September 2026, Hum Pathol.

On OnCo: Adult granulosa cell tumour of the ovary

Paper: Diffuse midline glioma, H3 K27-altered, forming a suprasellar mass: A case report.

2026-09-11T00:00:00Z

Published in Radiol Case Rep on 11 September 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.

11 September 2026, Radiol Case Rep.

On OnCo: Diffuse midline glioma, H3 K27-altered, MRI

Paper: Dynamic proton arc therapy sequencing optimization algorithm for brain stereotactic radiosurgery.

2026-09-11T00:00:00Z

Published in Phys Med Biol on 11 September 2026; matched the OnCo record for Proton arc therapy.

11 September 2026, Phys Med Biol.

On OnCo: Proton arc therapy

Paper: Effect of Thermal Softening of Endotracheal Tubes on Perioperative Respiratory Adverse Events in Children Undergoing Adenotonsillectomy: A Randomized Controlled Trial.

2026-09-11T00:00:00Z

Published in Paediatr Anaesth on 11 September 2026; matched the OnCo record for Placental-site trophoblastic tumour and epithelioid trophoblastic tumour.

11 September 2026, Paediatr Anaesth.

On OnCo: Placental-site trophoblastic tumour and epithelioid trophoblastic tumour

Paper: Effectiveness and safety of cefazolin vs antistaphylococcal penicillins for methicillin-susceptible Staphylococcus aureus bacteremia: a multicenter real-world evaluation using the international TriNetX database.

2026-09-11T00:00:00Z

Published in Antimicrob Agents Chemother on 11 September 2026; matched the OnCo record for Alveolar soft part sarcoma.

11 September 2026, Antimicrob Agents Chemother.

On OnCo: Alveolar soft part sarcoma

Paper: Endobronchial High-Dose-Rate Brachytherapy for Posttransplant-Associated Bronchial Stenosis: Extended Follow-up of Pulmonary Function and Subsequent Procedures.

2026-09-11T00:00:00Z

Published in Adv Radiat Oncol on 11 September 2026; matched the OnCo record for High-dose-rate brachytherapy.

11 September 2026, Adv Radiat Oncol.

On OnCo: High-dose-rate brachytherapy

Paper: Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.

2026-09-11T00:00:00Z

Published in JCO Precis Oncol on 11 September 2026; matched the OnCo record for Early triple-negative breast cancer.

11 September 2026, JCO Precis Oncol.

On OnCo: Early triple-negative breast cancer

Paper: Giant retroperitoneal dedifferentiated liposarcoma with intraperitoneal extension: A case report.

2026-09-11T00:00:00Z

Published in Radiol Case Rep on 11 September 2026; matched the OnCo record for Liposarcoma.

11 September 2026, Radiol Case Rep.

On OnCo: Liposarcoma

Paper: Incidental Thyroid Uptake on 18F-FES PET/CT Revealing Papillary Thyroid Carcinoma.

2026-09-11T00:00:00Z

Published in Clin Nucl Med on 11 September 2026; matched the OnCo record for FES PET.

11 September 2026, Clin Nucl Med.

On OnCo: FES PET, Fluoroestradiol F-18

Paper: Intensive Endoscopic Resection for Downstaging of Superficial Non-ampullary Duodenal Epithelial Tumor Burden in Familial Adenomatous Polyposis: A Single-center Retrospective Study on Long-term Clinical Outcome.

2026-09-11T00:00:00Z

Published in DEN Open on 11 September 2026; matched the OnCo record for Endoscopic resection.

11 September 2026, DEN Open.

On OnCo: Endoscopic resection, FAP

Paper: Interobserver Study on HDR Prostate-Human-Selected Versus AI-Selected Plans.

2026-09-11T00:00:00Z

Published in Adv Radiat Oncol on 11 September 2026; matched the OnCo record for High-dose-rate brachytherapy.

11 September 2026, Adv Radiat Oncol.

On OnCo: High-dose-rate brachytherapy

Paper: Latin American Consensus for the Diagnosis, Staging, and Treatment of Peripheral T-Cell Lymphoma Not Otherwise Specified.

2026-09-11T00:00:00Z

Published in JCO Glob Oncol on 11 September 2026; matched the OnCo record for Brentuximab vedotin.

11 September 2026, JCO Glob Oncol.

On OnCo: Brentuximab vedotin

Paper: Lymphocyte markers with CA125 and HE4 for diagnosing early endometrial cancer in postmenopausal women: case-control study.

2026-09-11T00:00:00Z

Published in J Obstet Gynaecol on 11 September 2026; matched the OnCo record for Endometrial cancer.

11 September 2026, J Obstet Gynaecol.

On OnCo: Endometrial cancer

Paper: Melanotic Oncocytic Metaplasia of the Nasopharynx: A Benign Mimic of Mucosal Melanoma.

2026-09-11T00:00:00Z

Published in Head Neck Pathol on 11 September 2026; matched the OnCo record for Mucosal melanoma.

11 September 2026, Head Neck Pathol.

On OnCo: Mucosal melanoma

Paper: Microglia stabilize sleep homeostasis via adenosine A3 receptor signaling.

2026-09-11T00:00:00Z

Published on 11 September 2026 after first appearing as a preprint; matched State.

11 September 2026.

On OnCo: State

Paper: MRI Features of Diffuse Glioneuronal Tumor with Oligodendroglioma-like features and Nuclear Clusters: A Case Report and Literature Review.

2026-09-11T00:00:00Z

Published in Curr Med Imaging on 11 September 2026; matched the OnCo record for Oligodendroglioma, IDH-mutant and 1p/19q-codeleted.

11 September 2026, Curr Med Imaging.

On OnCo: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted

Paper: Nanoadjuvant-based membrane poration boosts antitumor immunity via modulating mitochondrial metabolism to downregulate PD-L1 and upregulate STING.

2026-09-11T00:00:00Z

Published in Bioact Mater on 11 September 2026; matched the OnCo record for STING & innate immune agonists.

11 September 2026, Bioact Mater.

On OnCo: STING & innate immune agonists

Paper: Nerve injury-induced protein 2 preserves lysosomal membrane integrity to suppress ferroptosis.

2026-09-11T00:00:00Z

Published on 11 September 2026 after first appearing as a preprint; matched Iobenguane I-131.

11 September 2026.

On OnCo: Iobenguane I-131

Paper: Non-surgical therapies for localized non-melanoma skin cancer in older adults: A review.

2026-09-11T00:00:00Z

Published in J Geriatr Oncol on 11 September 2026; matched the OnCo record for Hedgehog pathway inhibitors.

11 September 2026, J Geriatr Oncol.

On OnCo: Hedgehog pathway inhibitors

Paper: Optimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentary.

2026-09-11T00:00:00Z

Published in Leuk Lymphoma on 11 September 2026; matched the OnCo record for Momelotinib.

11 September 2026, Leuk Lymphoma.

On OnCo: Momelotinib

Paper: p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications.

2026-09-11T00:00:00Z

Published in Cancer Treat Rev on 11 September 2026; matched the OnCo record for EGFR-mutated non-small-cell lung cancer.

11 September 2026, Cancer Treat Rev.

On OnCo: EGFR-mutated non-small-cell lung cancer

Paper: Papillary craniopharyngioma following an initial diagnosis of Rathke cleft cyst: a case report and narrative review.

2026-09-11T00:00:00Z

Published in JCEM Case Rep on 11 September 2026; matched the OnCo record for Craniopharyngioma.

11 September 2026, JCEM Case Rep.

On OnCo: Craniopharyngioma

Paper: Phase 1a clinical trial of XRD-0394, a first-in-class dual ATM/DNA-PK inhibitor, in combination with palliative radiotherapy.

2026-09-11T00:00:00Z

Published in Int J Radiat Oncol Biol Phys on 11 September 2026; matched the OnCo record for Palliative radiotherapy.

11 September 2026, Int J Radiat Oncol Biol Phys.

On OnCo: Palliative radiotherapy

Paper: Phenotypic and functional characterization of tumor-reactive T cells in malignant pleural effusions.

2026-09-11T00:00:00Z

Published on 11 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, TIL therapy and CD3.

11 September 2026.

On OnCo: Single-cell & spatial profiling, TIL therapy, CD3, Aldesleukin

Paper: Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial.

2026-09-11T00:00:00Z

Published in Eur J Cancer on 11 September 2026; matched the OnCo record for Panitumumab.

11 September 2026, Eur J Cancer.

On OnCo: Panitumumab

Paper: Quantitative dual-layer spectral CT parameters associated with a continuous improvement response pattern to CAPTEM in advanced gastroenteropancreatic neuroendocrine neoplasms.

2026-09-11T00:00:00Z

Published in Abdom Radiol (NY) on 11 September 2026; matched the OnCo record for Capecitabine + temozolomide.

11 September 2026, Abdom Radiol (NY).

On OnCo: Capecitabine + temozolomide

Paper: RE: Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or gemcitabine-nab-paclitaxel: a multinational analysis.

2026-09-11T00:00:00Z

Published in J Natl Cancer Inst on 11 September 2026; matched the OnCo record for Gemcitabine + nab-paclitaxel.

11 September 2026, J Natl Cancer Inst.

On OnCo: Gemcitabine + nab-paclitaxel

Paper: RE: Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis.

2026-09-11T00:00:00Z

Published in J Natl Cancer Inst on 11 September 2026; matched the OnCo record for Gemcitabine + nab-paclitaxel.

11 September 2026, J Natl Cancer Inst.

On OnCo: Gemcitabine + nab-paclitaxel

Paper: Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma.

2026-09-11T00:00:00Z

Published in Curr Treat Options Oncol on 11 September 2026; matched the OnCo record for GC101 TIL.

11 September 2026, Curr Treat Options Oncol.

On OnCo: GC101 TIL

Paper: Response to meeting STRIDE-II targets in routine practice: Assessment, access, and service design.

2026-09-11T00:00:00Z

Published in Saudi J Gastroenterol on 11 September 2026; matched the OnCo record for STRIDE DNA break detection.

11 September 2026, Saudi J Gastroenterol.

On OnCo: STRIDE DNA break detection

Paper: Risk factors for complications after cytoreductive surgery (CRS) and HIPEC in 290 peritoneal malignancies of primary and secondary origins.

2026-09-11T00:00:00Z

Published in Updates Surg on 11 September 2026; matched the OnCo record for Sodium thiosulfate.

11 September 2026, Updates Surg.

On OnCo: Sodium thiosulfate

Paper: Sacral benign notochordal cell tumor with atypical imaging features and 16-year spontaneous partial regression: A case report.

2026-09-11T00:00:00Z

Published in Radiol Case Rep on 11 September 2026; matched the OnCo record for Chordoma.

11 September 2026, Radiol Case Rep.

On OnCo: Chordoma

Paper: Small molecule inhibition of the mitochondrial lipid transfer protein STARD7 attenuates influenza viral replication.

2026-09-11T00:00:00Z

Published on 11 September 2026 after first appearing as a preprint; matched Iobenguane I-131.

11 September 2026.

On OnCo: Iobenguane I-131

Paper: Soluble P2X7 receptor (sP2X7R) as a marker of inflammation in pregnancy.

2026-09-11T00:00:00Z

Published on 11 September 2026 after first appearing as a preprint; matched State.

11 September 2026.

On OnCo: State

Paper: Synthetic lethality and context-selective DNA-damage response dependencies: from genetic vulnerability to pharmacological translation.

2026-09-11T00:00:00Z

Published in Drug Discov Today on 11 September 2026; matched the OnCo record for WRN helicase.

11 September 2026, Drug Discov Today.

On OnCo: WRN helicase

Paper: Tumor-derived CTHRC1 mediates ITGB3-dependent osteoclast differentiation to promote prostate cancer bone metastasis.

2026-09-11T00:00:00Z

Published on 11 September 2026 after first appearing as a preprint; matched SRC family kinases, Iobenguane I-131 and RANK ligand.

11 September 2026.

On OnCo: SRC family kinases, Iobenguane I-131, RANK ligand

Paper: Ultramutagenesis through Combined Msh2 Depletion and Proofreading-Deficient DNA Polymerase ε Expression Enhances Small-Molecule Target Identification in Forward Genetic Screens.

2026-09-11T00:00:00Z

Published on 11 September 2026 after first appearing as a preprint; matched Lurbinectedin, Bortezomib and Whole-exome & whole-genome sequencing.

11 September 2026.

On OnCo: Lurbinectedin, Bortezomib, Whole-exome & whole-genome sequencing, Proteasome, Iobenguane I-131

Paper: Ultrasound Features of Female Adnexal Tumor of Probable Wolffian Origin (FATWO): A Case Series and Literature Review.

2026-09-11T00:00:00Z

Published in Curr Med Imaging on 11 September 2026; matched the OnCo record for Adult granulosa cell tumour of the ovary.

11 September 2026, Curr Med Imaging.

On OnCo: Adult granulosa cell tumour of the ovary

Paper: Vorasidenib-Induced Acute Liver Injury.

2026-09-11T00:00:00Z

Published in Dig Dis Sci on 11 September 2026; matched the OnCo record for Vorasidenib.

11 September 2026, Dig Dis Sci.

On OnCo: Vorasidenib, MET, Prednisone

Paper: "Bendamustine monotherapy induces high response rates and STAT3 inhibition in high burden T-cell large granular lymphocytic leukemia".

2026-09-10T00:00:00Z

Published in Haematologica on 10 September 2026; matched the OnCo record for Bendamustine.

10 September 2026, Haematologica.

On OnCo: Bendamustine

Paper: 177Lu-FAPI-2286 Radioligand Therapy in Refractory Scalp Melanoma.

2026-09-10T00:00:00Z

Published in Clin Nucl Med on 10 September 2026; matched the OnCo record for Lutetium-177 dotatate.

10 September 2026, Clin Nucl Med.

On OnCo: Lutetium-177 dotatate

Paper: A framework for extraction of clinical information from radiological mammography reports using large language models and retrieval augmented generation.

2026-09-10T00:00:00Z

Published on 10 September 2026 after first appearing as a preprint; matched Mammography & tomosynthesis.

10 September 2026.

On OnCo: Mammography & tomosynthesis

Paper: Aneurysmal Bone Cyst of the Distal Phalanx: A Case Report.

2026-09-10T00:00:00Z

Published in J Hand Surg Glob Online on 10 September 2026; matched the OnCo record for MRI.

10 September 2026, J Hand Surg Glob Online.

On OnCo: MRI

Paper: Assessing the efficacy of adjuvant chemotherapy in patients with T3N0 gastric cancer.

2026-09-10T00:00:00Z

Published in Eur J Surg Oncol on 10 September 2026; matched the OnCo record for CAPOX.

10 September 2026, Eur J Surg Oncol.

On OnCo: CAPOX

Paper: Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.

2026-09-10T00:00:00Z

Published in Med Oncol on 10 September 2026; matched the OnCo record for MRTX1133.

10 September 2026, Med Oncol.

On OnCo: MRTX1133, Setidegrasib, Zoldonrasib

Paper: Bioinspired liquid metal-spidroin (LMS) stripe microneedle actuators.

2026-09-10T00:00:00Z

Published in Mater Today Bio on 10 September 2026; matched the OnCo record for Leiomyosarcoma.

10 September 2026, Mater Today Bio.

On OnCo: Leiomyosarcoma

Paper: Central nervous system management remains an evidence gap in first-line tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm. Comment on: "First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level".

2026-09-10T00:00:00Z

Published in Haematologica on 10 September 2026; matched the OnCo record for Blastic plasmacytoid dendritic cell neoplasm.

10 September 2026, Haematologica.

On OnCo: Blastic plasmacytoid dendritic cell neoplasm

Paper: Clinicopathological characteristics and surgical outcomes of primary hepatic perivascular epithelioid cell tumor (PEComa): A single-center cohort study.

2026-09-10T00:00:00Z

Published in Surg Oncol on 10 September 2026; matched the OnCo record for Perivascular epithelioid cell tumour.

10 September 2026, Surg Oncol.

On OnCo: Perivascular epithelioid cell tumour

Paper: Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics.

2026-09-10T00:00:00Z

Published in Cytometry B Clin Cytom on 10 September 2026; matched the OnCo record for Systemic mastocytosis.

10 September 2026, Cytometry B Clin Cytom.

On OnCo: Systemic mastocytosis

Paper: Comparative analysis of robotic- and endoscopic-assisted minimally invasive nipple-areola complex-sparing mastectomy for breast cancer: a meta-analysis with subgroup analyses.

2026-09-10T00:00:00Z

Published on 10 September 2026 after first appearing as a preprint; matched Robotic & minimally invasive surgery.

10 September 2026.

On OnCo: Robotic & minimally invasive surgery

Paper: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.

2026-09-10T00:00:00Z

Published in Bone Marrow Transplant on 10 September 2026; matched the OnCo record for Alemtuzumab.

10 September 2026, Bone Marrow Transplant.

On OnCo: Alemtuzumab

Paper: Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiotherapy for Locally Advanced Pancreatic Cancer.

2026-09-10T00:00:00Z

Published in Int J Radiat Oncol Biol Phys on 10 September 2026; matched the OnCo record for Carbon-ion therapy.

10 September 2026, Int J Radiat Oncol Biol Phys.

On OnCo: Carbon-ion therapy

Paper: Coronary artery calcification score as a prognostic factor in patients undergoing allogeneic stem cell transplantation - a retrospective analysis.

2026-09-10T00:00:00Z

Published in Cardiooncology on 10 September 2026; matched the OnCo record for Allogeneic stem cell transplantation.

10 September 2026, Cardiooncology.

On OnCo: Allogeneic stem cell transplantation

Paper: Current Status and Unmet Needs of EUS Education in Japan: A Nationwide Survey Focusing on Screening EUS, EUS-Guided Sampling, and Interventional EUS.

2026-09-10T00:00:00Z

Published in DEN Open on 10 September 2026; matched the OnCo record for Iobenguane I-131.

10 September 2026, DEN Open.

On OnCo: Iobenguane I-131, Ultrasound

Paper: CXCR4-directed liposomal co-delivery of cytarabine and AMD3100 for redox-associated chemosensitization in acute myeloid leukemia.

2026-09-10T00:00:00Z

Published in Colloids Surf B Biointerfaces on 10 September 2026; matched the OnCo record for Plerixafor.

10 September 2026, Colloids Surf B Biointerfaces.

On OnCo: Plerixafor

Paper: Cytokine concentrations in pediatric primary mediastinal large B cell lymphoma correlate with disease extent and outcome.

2026-09-10T00:00:00Z

Published in Blood Adv on 10 September 2026; matched the OnCo record for Primary mediastinal (thymic) large B-cell lymphoma.

10 September 2026, Blood Adv.

On OnCo: Primary mediastinal (thymic) large B-cell lymphoma

Paper: Disseminated HIV-Associated Burkitt Lymphoma With Cardiac and Presumed Central Nervous System Involvement.

2026-09-10T00:00:00Z

Published in JACC Case Rep on 10 September 2026; matched the OnCo record for Burkitt lymphoma.

10 September 2026, JACC Case Rep.

On OnCo: Burkitt lymphoma

Paper: Dose-Registered CT assessment of radiation-induced lung injury after chemoradiotherapy for stage III NSCLC.

2026-09-10T00:00:00Z

Published in Ann Med on 10 September 2026; matched the OnCo record for Durvalumab.

10 September 2026, Ann Med.

On OnCo: Durvalumab, Volumetric modulated arc therapy

Paper: Enabling Evolutionary Therapy in metastatic cancer lacking serum biomarkers.

2026-09-10T00:00:00Z

Published in J Evol Biol on 10 September 2026; matched the OnCo record for Platinum-sensitive ovarian cancer.

10 September 2026, J Evol Biol.

On OnCo: Platinum-sensitive ovarian cancer

Paper: ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma.

2026-09-10T00:00:00Z

Published in Pediatr Blood Cancer on 10 September 2026; matched the OnCo record for Nelarabine.

10 September 2026, Pediatr Blood Cancer.

On OnCo: Nelarabine

Paper: Epithelioid sarcoma: A retrospective review from a single centre tertiary orthopaedic sarcoma unit.

2026-09-10T00:00:00Z

Published in Eur J Surg Oncol on 10 September 2026; matched the OnCo record for Epithelioid sarcoma.

10 September 2026, Eur J Surg Oncol.

On OnCo: Epithelioid sarcoma

Paper: Fibrotic Substrate Stiffness Enhances Endometriotic Epithelial Cell Motility.

2026-09-10T00:00:00Z

Published on 10 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling and State.

10 September 2026.

On OnCo: Single-cell & spatial profiling, State

Paper: First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability.

2026-09-10T00:00:00Z

Published in Haematologica on 10 September 2026; matched the OnCo record for Asciminib.

10 September 2026, Haematologica.

On OnCo: Asciminib

Paper: Genetic Basis of Pancreatic Steatosis: A Systematic Review of Comparison between African and Non-African Populations.

2026-09-10T00:00:00Z

Published in Physiol Genomics on 10 September 2026; matched the OnCo record for PLUTO.

10 September 2026, Physiol Genomics.

On OnCo: PLUTO

Paper: Gypenosides ameliorate polycystic ovary syndrome via gut microbiota modulation: An integrated gut microbiome and ovarian transcriptome study.

2026-09-10T00:00:00Z

Published in iScience on 10 September 2026; matched the OnCo record for Letrozole.

10 September 2026, iScience.

On OnCo: Letrozole

Paper: Image-guided ablation for pediatric malignant solid tumors: a review of modalities, evidence, and clinical applications.

2026-09-10T00:00:00Z

Published in Pediatr Radiol on 10 September 2026; matched the OnCo record for Electrochemotherapy.

10 September 2026, Pediatr Radiol.

On OnCo: Electrochemotherapy

Paper: Impact of defibrotide on survival in sinusoidal obstruction syndrome / veno-occlusive disease: a retrospective cohort study comparing two sequential treatment eras.

2026-09-10T00:00:00Z

Published in Hematology on 10 September 2026; matched the OnCo record for Defibrotide.

10 September 2026, Hematology.

On OnCo: Defibrotide

Paper: Improved quality of life and prolonged survival with add-on homeopathic treatment in patients with non-small cell lung cancer: a prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study.

2026-09-10T00:00:00Z

Published in Support Care Cancer on 10 September 2026; matched the OnCo record for Homeopathy.

10 September 2026, Support Care Cancer.

On OnCo: Homeopathy

Paper: Inhibiting glioma cell invasion by sequential photo-sonodynamic therapy.

2026-09-10T00:00:00Z

Published on 10 September 2026 after first appearing as a preprint; matched Focused ultrasound & histotripsy, Photoimmunotherapy & photodynamic therapy and Sonodynamic therapy.

10 September 2026.

On OnCo: Focused ultrasound & histotripsy, Photoimmunotherapy & photodynamic therapy, Sonodynamic therapy, 5-Aminolevulinic acid, Aminolevulinic acid

Paper: Interpretable four-class machine learning prediction of initial I-131 therapy responses in differentiated thyroid cancer.

2026-09-10T00:00:00Z

Published in Ann Med on 10 September 2026; matched the OnCo record for Radioactive iodine.

10 September 2026, Ann Med.

On OnCo: Radioactive iodine, Thyroglobulin, calcitonin and CEA in thyroid cancer follow-up, Thyroid cancer

Paper: Intra- and intertumoral discordance of Claudin-18.2: a systematic review and meta-analysis.

2026-09-10T00:00:00Z

Published in ESMO Gastrointest Oncol on 10 September 2026; matched the OnCo record for Claudin 18.2.

10 September 2026, ESMO Gastrointest Oncol.

On OnCo: Claudin 18.2, Histopathology & immunohistochemistry

Paper: Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study.

2026-09-10T00:00:00Z

Published in Haematologica on 10 September 2026; matched the OnCo record for Ixazomib.

10 September 2026, Haematologica.

On OnCo: Ixazomib

Paper: Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics.

2026-09-10T00:00:00Z

Published in Cancer Metastasis Rev on 10 September 2026; matched the OnCo record for Cobimetinib.

10 September 2026, Cancer Metastasis Rev.

On OnCo: Cobimetinib, MEK1/2, CRAF

Paper: Large language model-based evaluation of the impact of gender in medical research.

2026-09-10T00:00:00Z

Published on 10 September 2026 after first appearing as a preprint; matched AI trial matching & clinical decision support.

10 September 2026.

On OnCo: AI trial matching & clinical decision support

Paper: Late Endocrine and Organ Toxicities After Treosulfan-Based Conditioning in Pediatric Hematopoietic Cell Transplantation: A Systematic Review.

2026-09-10T00:00:00Z

Published in Pediatr Blood Cancer on 10 September 2026; matched the OnCo record for Busulfan.

10 September 2026, Pediatr Blood Cancer.

On OnCo: Busulfan, Treosulfan

Paper: Leveraging neural network models for drug repurposing: a case study on cardiac hypertrophy.

2026-09-10T00:00:00Z

Published on 10 September 2026 after first appearing as a preprint; matched Lapatinib and Iobenguane I-131.

10 September 2026.

On OnCo: Lapatinib, Iobenguane I-131

Paper: Live dynamics of induced cell-cell fusion between mitotic and interphasic cells.

2026-09-10T00:00:00Z

Published on 10 September 2026 after first appearing as a preprint; matched State.

10 September 2026.

On OnCo: State

Paper: Longitudinal assessment of functional antibodies to a novel influenza virus strain across age groups.

2026-09-10T00:00:00Z

Published on 10 September 2026 after first appearing as a preprint; matched State.

10 September 2026.

On OnCo: State

Paper: Neuroendocrine Differentiation in Synovial Sarcoma-An Immunohistochemical Study of 357 Tumors With 4 Markers: Chromogranin A, Synaptophysin, Insulinoma-associated Protein 1 and Insulin Gene Enhancer Protein ISL-1.

2026-09-10T00:00:00Z

Published in Appl Immunohistochem Mol Morphol on 10 September 2026; matched the OnCo record for Synovial sarcoma.

10 September 2026, Appl Immunohistochem Mol Morphol.

On OnCo: Synovial sarcoma

Paper: Oligosaccharide adjuvant-deferred antigen endocytosis promotes cross-presentation.

2026-09-10T00:00:00Z

Published in Bioact Mater on 10 September 2026; matched the OnCo record for Nicotinamide.

10 September 2026, Bioact Mater.

On OnCo: Nicotinamide

Paper: Optimizing cord blood unit selection to improve survival after single-unit unrelated cord blood transplantation for adult myelodysplastic syndrome.

2026-09-10T00:00:00Z

Published in Br J Haematol on 10 September 2026; matched the OnCo record for Higher-risk myelodysplastic syndromes.

10 September 2026, Br J Haematol.

On OnCo: Higher-risk myelodysplastic syndromes, Lower-risk myelodysplastic syndromes

Approval: Approval: Daraxonrasib (US)

2026-08-26T00:00:00Z

NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

26 August 2026, FDA.

On OnCo: Daraxonrasib, Pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, Non-small-cell lung cancer, Colorectal cancer

Approval: FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

2026-08-26T00:00:00Z

On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

26 August 2026, FDA.

On OnCo: Daraxonrasib

Preprint: Accurate and scalable decontamination of imaging-based spatial transcriptomics via optimal transport

2026-09-15T00:00:00Z

Posted on bioRxiv on 15 September 2026; not peer reviewed; matched Single-cell & spatial profiling and Spatial transcriptomics.

15 September 2026, bioRxiv.

On OnCo: Single-cell & spatial profiling, Spatial transcriptomics

Preprint: An outcome-blind H&E architecture score is associated with prostate cancer-specific mortality

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched Pathology & radiology foundation models and Prov-GigaPath.

15 September 2026, Research Square.

On OnCo: Pathology & radiology foundation models, Prov-GigaPath

Preprint: An Oxidative Stress-Associated Seven-Gene Prognostic Signature in Lung Adenocarcinoma: Integrative Transcriptomic Analysis Across Public Cohorts

2026-09-15T00:00:00Z

Posted on bioRxiv on 15 September 2026; not peer reviewed; matched AKT and Atlas.

15 September 2026, bioRxiv.

On OnCo: AKT, Atlas

Preprint: CD163 Expression as an Independent Prognostic Biomarker in Glioblastoma: A Digital Pathology and Survival Analysis Study

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched Histopathology & immunohistochemistry and Iobenguane I-131.

15 September 2026, Research Square.

On OnCo: Histopathology & immunohistochemistry, Iobenguane I-131

Preprint: Construct validity and evidence boundaries of a 17-gene transcriptomic proxy for mitoxyperilysis in colorectal aging and cancer Analysis

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched MET.

15 September 2026, Research Square.

On OnCo: MET

Preprint: Context-dependent rewiring of autocrine TGFβ/RhoA/ROCK1 under complete vs deprived serum conditions in TNBC transduced cells

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched Iobenguane I-131.

15 September 2026, Research Square.

On OnCo: Iobenguane I-131

Preprint: Cost-effectiveness and carbon footprint of cystoscopic surveillance schedules in non-muscle-invasive bladder cancer

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched State.

15 September 2026, Research Square.

On OnCo: State

Preprint: Cranial Radiotherapy Combined with Afatinib in Non-Small Cell Lung Cancer Patients with EGFR G719X+S768I Co-Mutations and Brain Metastases: A Retrospective Study

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched Nintedanib, EGFR and Afatinib.

15 September 2026, Research Square.

On OnCo: Nintedanib, EGFR, Afatinib, Iobenguane I-131

Preprint: Cross-cohort evaluation of thyroid ultrasound deep learning across different outcome definitions: a duplicate-controlled benchmark

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched Ultrasound.

15 September 2026, Research Square.

On OnCo: Ultrasound

Preprint: Cross-Source Progression Assessment in Advanced Pancreatic Cancer: An Opportunity-Adjusted Six-State Analysis

2026-09-15T00:00:00Z

Posted on medRxiv on 15 September 2026; not peer reviewed; matched State.

15 September 2026, medRxiv.

On OnCo: State

Preprint: DFT-based prediction of anti-cancer activity of some organo-Pt IV complexes

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched Cisplatin, Platinum agents and Carboplatin.

15 September 2026, Research Square.

On OnCo: Cisplatin, Platinum agents, Carboplatin, Oxaliplatin

Preprint: Drug–Drug Interactions in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated with Immunotherapy: A Multicenter Cohort Study

2026-09-15T00:00:00Z

Posted on Preprints.org on 15 September 2026; not peer reviewed; matched Immune checkpoint inhibitors, Pembrolizumab and Nivolumab.

15 September 2026, Preprints.org.

On OnCo: Immune checkpoint inhibitors, Pembrolizumab, Nivolumab

Preprint: Evaluating Patient Satisfaction with Oncology Pharmacy Services in Regional Referral Centers: A Mixed-Methods Approach

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched Iobenguane I-131.

15 September 2026, Research Square.

On OnCo: Iobenguane I-131

Preprint: Evaluation of CBCT-based HU correction for synthetic CT generation in head-and-neck radiotherapy: FOV-stratified and peripheral-region analysis

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched IMRT / IGRT.

15 September 2026, Research Square.

On OnCo: IMRT / IGRT

Preprint: Germline pharmacogenomic predictors of treatment-related toxicity in non-small cell lung cancer: a systematic review of the discovery-to-implementation gap

2026-09-15T00:00:00Z

Posted on Research Square on 15 September 2026; not peer reviewed; matched Nintedanib, PD-1 and KRAS.

15 September 2026, Research Square.

On OnCo: Nintedanib, PD-1, KRAS, TP53

Approval: FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma

2026-08-25T00:00:00Z

On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir.

25 August 2026, FDA.

On OnCo: Tislelizumab, Zanidatamab, Platinum + etoposide, Gastric & gastro-oesophageal junction cancer, Oesophageal cancer, Non-small-cell lung cancer, Hepatocellular carcinoma, Recurrent and metastatic nasopharyngeal carcinoma, Biliary tract cancer, HER2

Approval: FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

2026-08-13T00:00:00Z

On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

13 August 2026, FDA.

On OnCo: Dexamethasone, Daratumumab, Iberdomide, Multiple myeloma, Smouldering multiple myeloma, Newly diagnosed multiple myeloma, transplant-eligible, Newly diagnosed multiple myeloma, transplant-ineligible, Plasma cell leukaemia, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, Hodgkin lymphoma

Approval: FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

2026-08-06T00:00:00Z

On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

6 August 2026, FDA.

On OnCo: Vusolimogene oderparepvec, Nivolumab, Relatlimab + nivolumab, Melanoma, Non-small-cell lung cancer, Renal cell carcinoma, Hodgkin lymphoma, Colorectal cancer

Approval: Approval: Amivantamab (US)

2026-07-31T00:00:00Z

Subcutaneous formulation (PALOMA-3).

31 July 2026, FDA.

On OnCo: Amivantamab, Non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR, MET, ArteraAI Breast, HR-positive / HER2-negative breast cancer, Atezolizumab, Small-cell lung cancer, Hepatocellular carcinoma, Advanced hepatocellular carcinoma, Bladder & urothelial cancer, Belantamab mafodotin, Multiple myeloma, Relapsed or refractory multiple myeloma, BCMA, Cemiplimab, Melanoma, PD-L1-high non-small-cell lung cancer without a driver mutation, Cutaneous squamous cell carcinoma, Advanced cutaneous squamous cell carcinoma, Durvalumab, Biliary tract cancer, Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma, Encorafenib, Colorectal cancer, BRAF V600E-mutant colorectal cancer, BRAF V600E-mutant non-small-cell lung cancer, Lutetium-177 vipivotide tetraxetan, Prostate cancer, Metastatic castration-resistant prostate cancer, Metastatic hormone-sensitive prostate cancer, PSMA, Nivolumab, Renal cell carcinoma, Hodgkin lymphoma, Optune / Optune Pax, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Mesothelioma, Pembrolizumab, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Triple-negative breast cancer, Head and neck squamous cell carcinoma, Piflufolastat F-18 / Pylarify TruVu, Relacorilant, Ovarian cancer, Platinum-resistant ovarian cancer, Advanced and metastatic adrenocortical carcinoma, Revumenib, Acute myeloid leukaemia, Acute lymphoblastic leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Menin, Satricabtagene autoleucel, Gastric & gastro-oesophageal junction cancer, Claudin 18.2, Tarlatamab, Extensive-stage small-cell lung cancer, Limited-stage small-cell lung cancer, DLL3, CD3, Teclistamab, Trastuzumab deruxtecan, HER2-positive breast cancer, HER2-positive gastric cancer, Vepdegestrant, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Estrogen receptor, Vusolimogene oderparepvec, Advanced melanoma, Zenocutuzumab, KRAS wild-type pancreatic ductal adenocarcinoma, HER2, Zongertinib, HER2-mutant non-small-cell lung cancer

Approval: FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

2026-07-31T00:00:00Z

On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).

31 July 2026, FDA.

On OnCo: Lutetium-177 vipivotide tetraxetan, Prostate cancer

Approval: FDA approves zidesamtinib for ROS1 -positive non-small cell lung cancer

2026-07-22T00:00:00Z

On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

22 July 2026, FDA.

On OnCo: Zidesamtinib, Non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer

Approval: FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

2026-07-14T00:00:00Z

On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.

14 July 2026, FDA.

On OnCo: Fulvestrant, Palbociclib, Gedatolisib, HR-positive / HER2-negative breast cancer, Estrogen receptor, HR-positive metastatic breast cancer after CDK4/6 inhibitors, PIK3CA / PI3K-alpha, AKT, HER2-positive breast cancer, CDK4/6

Approval: FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

2026-07-14T00:00:00Z

On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

14 July 2026, FDA.

On OnCo: Selpercatinib, Thyroid cancer, Non-small-cell lung cancer, Medullary thyroid cancer, Papillary thyroid cancer, RET fusion-positive non-small-cell lung cancer

Approval: FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

2026-07-10T00:00:00Z

On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC).

10 July 2026, FDA.

On OnCo: Enfortumab vedotin, Pembrolizumab, Gemcitabine + cisplatin, Cisplatin, Bladder & urothelial cancer, Muscle-invasive and advanced bladder cancer, Nectin-4, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Triple-negative breast cancer, Non-small-cell lung cancer, Melanoma, Head and neck squamous cell carcinoma

Approval: FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

2026-07-09T00:00:00Z

On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S.

9 July 2026, FDA.

On OnCo: Isatuximab, Multiple myeloma, Newly diagnosed multiple myeloma, transplant-ineligible, CD38

Withdrawal: Withdrawal: Zelenectide pevedotin (US)

2026-03-01T00:00:00Z

Programme deprioritised after regulatory feedback on Duravelo-2 design.

March 2026, FDA.

On OnCo: Zelenectide pevedotin, Bladder & urothelial cancer, Nectin-4

Result: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor: Phase 3 result

2026-01-01T00:00:00Z

For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).

2026, ClinicalTrials.gov.

On OnCo: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor, Lazertinib, Non-small-cell lung cancer, Small-cell lung cancer, EGFR-mutated non-small-cell lung cancer

Result: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair: Phase 3 result

2026-01-01T00:00:00Z

Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.

2026, ClinicalTrials.gov.

On OnCo: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair, Abiraterone acetate, Niraparib, Prednisone, Prostate cancer, Metastatic hormone-sensitive prostate cancer

Result: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: Phase 3 result

2026-01-01T00:00:00Z

Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.

2026, ClinicalTrials.gov.

On OnCo: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma, Lenvatinib, Hepatocellular carcinoma, Advanced hepatocellular carcinoma

Result: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S: Phase 3 result

2026-01-01T00:00:00Z

Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.

2026, ClinicalTrials.gov.

On OnCo: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S, Osimertinib, Cisplatin, Carboplatin, Pemetrexed, Non-small-cell lung cancer

Result: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma: Phase 3 result

2026-01-01T00:00:00Z

Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.

2026, ClinicalTrials.gov.

On OnCo: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma, Nivolumab, Relatlimab + nivolumab, Melanoma, Advanced melanoma

Result: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance: Phase 3 result

2026-01-01T00:00:00Z

Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.

2026, ClinicalTrials.gov.

On OnCo: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance, Nivolumab, Renal cell carcinoma, Clear cell renal cell carcinoma

Result: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer: Phase 3 result

2026-01-01T00:00:00Z

Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.

2026, ClinicalTrials.gov.

On OnCo: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer, Osimertinib, Non-small-cell lung cancer, Small-cell lung cancer

Result: A Study to Investigate Tolerability and Efficacy of Asciminib: Phase 3 result

2026-01-01T00:00:00Z

Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.

2026, ClinicalTrials.gov.

On OnCo: A Study to Investigate Tolerability and Efficacy of Asciminib, Asciminib, Nilotinib, Chronic myeloid leukaemia, Chronic myeloid leukaemia, chronic phase

Result: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi: Phase 3 result

2026-01-01T00:00:00Z

Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.

2026, ClinicalTrials.gov.

On OnCo: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi, Luspatercept, Myeloproliferative neoplasms, Primary myelofibrosis

Result: BL-B01D1-307: Phase 3 result

2026-01-01T00:00:00Z

PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).

2026, onclive.com.

On OnCo: BL-B01D1-307, Izalontamab brengitecan, Triple-negative breast cancer

Result: CLARITY-Gastric 01: Phase 3 result

2026-01-01T00:00:00Z

Co-primary endpoints including OS met (July 2026); numbers pending.

2026, cancernetwork.com.

On OnCo: CLARITY-Gastric 01, Sonesitatug vedotin, Ramucirumab, Gastric & gastro-oesophageal junction cancer, Claudin 18.2

Result: DeLLphi-305: Phase 3 result

2026-01-01T00:00:00Z

Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.

2026, amgen.com.

On OnCo: DeLLphi-305, Tarlatamab, Durvalumab, Small-cell lung cancer, Extensive-stage small-cell lung cancer, DLL3

Result: DREAM3R: Phase 3 result

2026-01-01T00:00:00Z

Stopped early; primary endpoint not met.

2026, ClinicalTrials.gov.

On OnCo: DREAM3R, Durvalumab, Pemetrexed, Mesothelioma

Result: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy: Phase 2/3 result

2026-01-01T00:00:00Z

Overall Survival (OS) (Arm A Versus Arm C): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 months versus Docetaxel (Arm C) 11.3 months, hazard ratio 0.85.

2026, ClinicalTrials.gov.

On OnCo: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy, Cobolimab, Non-small-cell lung cancer

Result: EMERALD-3: Phase 3 result

2026-01-01T00:00:00Z

PFS HR ~0.70 (interim); OS immature.

2026, astrazeneca.com.

On OnCo: EMERALD-3, Durvalumab, Tremelimumab, Lenvatinib, Hepatocellular carcinoma, Intermediate hepatocellular carcinoma

Withdrawal: EU withdrawal: Duvelisib

2026-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).

2026, European Commission (EMA opinion).

On OnCo: Duvelisib, Chronic lymphocytic leukaemia, Peripheral T-cell lymphomas, PIK3CA / PI3K-alpha

Withdrawal: EU withdrawal: Lifileucel

2025-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).

2025, European Commission (EMA opinion).

On OnCo: Lifileucel, Melanoma, Non-small-cell lung cancer, Advanced melanoma

Law: European Health Data Space Regulation (EU) 2025/327

2025-01-01T00:00:00Z

A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.

2025, European Union, regulation.

On OnCo: European Health Data Space Regulation (EU) 2025/327, GDPR and health data, Oncology EHR and real-world data platforms, Real-world evidence

OnCo Edge

Paper: Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care.

Paper: Phase III Trials Test First-Line Options in Advanced NSCLC.

Paper: γδ T cells modulate anti-tumor immunity in small cell lung cancer.

Paper: An expert-level generalist AI for abdominal CT diagnosis.

Paper: Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.

Paper: Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma.

Paper: Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

Paper: Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA-Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer.

Paper: Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

Paper: Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

Approval: FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer

Issue: OnCo weekly, 2026-09-22

Paper: Successful management of paediatric chronic SIAD with oral urea: report of two cases.

Paper: Author Correction: Erythropoietin receptor on cDC1s dictates immune tolerance.

Paper: Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS<sup>G12D</sup> mutations: a phase 1 trial.

Paper: A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

Paper: Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy.

Paper: Comparative Effectiveness of Antibiotic Prophylaxis Regimens in Pediatric Acute Myeloid Leukemia.

Paper: IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.

Paper: Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation.

Paper: Integrative Genetic and Bioinformatic Analysis of Androgen Pathway Gene Polymorphisms, Testosterone, and PSA Levels in Prostate Cancer.

Issue: OnCo weekly, 2026-09-21

Paper: Real-world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study.

Paper: Ribonucleotides Amplify Mitochondrial DNA-Driven cGAS-STING Activation via FdUMP-ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy.

Paper: Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

Paper: Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.

Paper: Toripalimab Plus TPF as Induction Chemoimmunotherapy for the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Prospective Phase II Study.

Paper: Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

Paper: Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.

Paper: P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in <i>EGFR</i>-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

Paper: Advancing neurofibromatosis research: a comparative review of animal models and their utility in dissecting the tumor microenvironment.

Paper: Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research.

Paper: Bridging the data latency gap: automated extraction of genomic biomarkers from unstructured clinical documents to support real-world oncology data.

Paper: Current Management and Investigational Therapeutic Strategies in Penile Squamous Cell Carcinoma: A Narrative Review.

Paper: Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand? Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand?

Paper: Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.

Paper: Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

Paper: Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2.

Paper: Longitudinal Associations of Oxaliplatin Treatment With Chemotherapy-Induced Peripheral Neuropathy in Colorectal cancer Survivors up to 2 Years Post-Treatment.

Paper: Predictors of perceived value of multi-cancer early detection testing: a national PRECEDE-PROCEED framework study.

Paper: Progress with FAK inhibitors in the patent literature (2020-present).

Paper: Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.

Paper: Updates to contemporary care of glioblastoma.

Paper: A pyridone-fused imidazo[1,2-a]pyridine hybrid binds to tubulin at the vinblastine site, depolymerizes microtubules and inhibits Cancer cell proliferation.

Paper: Acute myeloid leukemia arising in treated chronic lymphocytic leukemia/small lymphocytic lymphoma: a challenge in analysis of lineage relationship.

Paper: Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers.

Paper: Clinicopathologic Characteristics of Somatic <i>TP53</i> Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.

Paper: Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

Paper: Distribution, socioeconomic inequalities and contributing factors of anaemia prevalence across wealth index among Indian adolescent girls: multivariate decomposition analysis of nationally representative survey.

Paper: Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study.

Paper: Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.

Paper: Hepatocellular Carcinoma With a Grade 3 Neuroendocrine Tumor Component: A Case Report.

Paper: Immunogenic cell death as a mechanism of synergy between sunitinib and <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.

Paper: In vivo CAR‑T cell therapy: mechanisms, clinical advances and optimization strategies.

Paper: Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen.

Paper: Investigating the impact of margins on the management of oropharyngeal cancer treated with transoral robotic surgery: a survey of head and neck oncologists' treatment patterns.

Paper: IRF1-driven chromatin and transcriptional regulation determines the anti-tumor responses to all-trans retinoic acid across cancer types.

Paper: Precision therapeutic strategies for advanced gastrointestinal stromal tumors.

Paper: Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT.

Paper: Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA.

Paper: Salivary Duct Carcinoma With Rhabdoid and Signet-Ring Cell Features Mimicking Invasive Lobular Carcinoma of the Breast: A Case Report and Review of the Literature.

Paper: Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.

Paper: Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Paper: Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.

Paper: Transoral Robotic Surgery (TORS) versus radical radiotherapy following neoadjuvant therapy for oropharyngeal carcinoma: a multicenter, real-world efficacy and safety analysis.

Paper: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.

Paper: [Corrigendum] The interaction between miR‑148a and DNMT1 suppresses cell migration and invasion by reactivating tumor suppressor genes in pancreatic cancer.

Paper: [Update on anal dysplasia and anal cancer].

Paper: A canonical role of SMAD4 in safeguarding 3D genome architecture to suppress lung tumorigenesis.

Paper: A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer.

Paper: A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

Paper: Acute Myocardial Infarction in Head and Neck Cancer Patients and Survivors: A Population-Based Cohort Study of Patient, Disease, and Treatment Factors.

Paper: Anagrelide remodels the PDE3A-SLFN12 interactome to associate with translation initiation machinery in cancer cell lines.

Paper: Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation.

Paper: Beyond Anatomical Resectability: A Hypermetabolic and Highly Aggressive Subtype of Spinal Chordoma Associated with Cancer-Specific Progression.

Paper: Can early <sup>68</sup>Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium.

Paper: Carbohydrate-Directed Labeling Probes for UV-Independent Chemoproteomic Profiling of Carbohydrate-Protein Interactions.

Paper: Chemotherapy Versus Surgery for Stage IIA Nonseminomatous Germ Cell Tumor: A Comparative Cost Utility Analysis.

Paper: Class visualizations and activation atlases for computational pathology.